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Abstract 
Chronic lung diseases are complex, progressive disorders with increasing incidence and 
mortality. Chronic obstructive pulmonary disease (COPD), asthma and pulmonary 
fibrosis are examples of chronic lung conditions that can significantly impact the quality 
of life. Minimally-invasive diagnostic methods that eliminate bronchoscopic and surgical 
biopsy from patients are ideal; metabolomics therefore holds considerable promise for 
the discovery of biomarkers that can aid diagnosis and treatment with greater sensitivity, 
specificity and precision.  
The main aim of this project was to employ ultra-performance liquid chromatography-
quadrupole time-of-flight (UPLC-QTOF) high resolution mass spectrometry (HRMS) 
and matrix-assisted laser desorption ionisation (MALDI) mass spectral imaging (MSI) 
together with multivariate statistics-based metabolomics to identify and characterize 
potential lipid biomarkers of idiopathic pulmonary fibrosis (IPF). This dissertation 
consists of the following studies: (1) literature review of metabolomics in chronic lung 
diseases; (2) application of HRMS for untargeted metabolic profiling of chronic lung 
disease including COPD and IPF; (3) investigation of a novel data-independent 
acquisition (DIA) approach to augment untargeted approaches for lipid biomarker 
identification; (4) development of a novel matrix application technique to improve 
MALDI-MSI acquisitions of tissue sections whilst maintaining spatial localisation of 
endogenous metabolites; and  (5) exploiting potassium adduct formation to resolve the 
spatial distribution of lipids in fibrotic tissues. 
A total of 65 clinical plasma samples (from 20 healthy control subjects, 21 COPD and 24 
IPF patients) were profiled using UHPLC-QTOF-MS. A fundamental challenge in using 
HRMS for untargeted profiling of complex, chronic lung diseases is the heterogeneity of 
the human samples. Various contaminations present in fibrotic tissues or adjacent non-
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fibrotic constituents can confound characterization and encumber the discovery of 
reliable biomarkers. The results of this study revealed significant correlation between 
COPD and IPF clinical phenotypes and plasma metabolite profiles. The unbiased 
metabolomics workflow and deconvolution pipeline provided end-to-end analysis from 
peak picking and annotation through to metabolite identification.  
Subsequently, the ability of the UPLC-QTOF-MS method to discriminate between lipid 
species was enhanced by the application of a DIA method to distinguish between “stable 
versus progressor” IPF patients. This DIA method is known as SONAR and uses a wide, 
continuously sliding precursor window for fragmentation, thereby allowing correlation 
of precursor and fragment ions. SONAR lipid data were processed using Progenesis QI 
and searched against LIPID MAPS for structural elucidation and metabolite confirmation. 
The lipids identified were found to be intermediates of key metabolic pathways such as 
the glycolytic/TCA cycle, mitochondrial-beta oxidation and lipid metabolism and hold 
considerable promise as biomarkers of disease.  
The matrix deposition step in MALDI-MSI is crucial for simultaneous extraction of 
metabolites from tissue sections as well as maintaining the spatial dimensionality of the 
endogenous metabolites. A novel, efficient and cost-effective preparative method referred 
to as the “freeze-spot” method was developed using wheat seed sections to demonstrate 
extraction efficiency and reliability, whilst maintaining the spatial resolution of the 
acquired MALDI-MSI images. The technique was also found to be simple and robust, 
forming fine matrix crystals that enabled efficient ionisation of surface metabolites, 
further eliminating the need for sophisticated matrix application approaches.  
In the final study, 10 healthy and 10 fibrotic tissues were compared using MALDI-MSI. 
The MSI technique developed uses potassium adduct formation to improve spatial 
resolution and dimensionality of lipid species such as triglycerides (TG), ceramides, 
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sphingolipids and glycerophospholipids. The results of this study showed changes in lipid 
composition of IPF tissues compared to healthy controls. This study identified 
lysophosphatidylcholine (LysoPC), phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) as potential lipid biomarkers of the disease and requires 
further study as targets of intervention and treatment. Both SONAR and MSI successfully 
identified similar classes of lipids (TG, PE, LysoPC and PC) which may play a role in the 
pathophysiology of the IPF lipidome. 
This project highlighted the complementarity of HRMS and MSI based metabolomics for 
the characterization of unique lipid features in fibrotic tissue and plasma samples. The 
study also demonstrated the discriminative power of the unbiased DIA approach for the 
identification of lipids via fragment ion patterns that were indicative of specific lipid 
classes. In addition, the application of chemometric principal component analysis (PCA) 
and orthogonal partial least-squares to latent structures-direct analysis (OPLS-DA) 
proved useful for the identification of statistically significant lipids. This statistical 
approach allowed for the assessment of covariance and correlation between lipids and the 
modelled lung diseases, and further illustrated lipid compositional changes in chronic 
lung diseases. 
Taken together, the experimental work presented in this thesis show the large potential 
for mass spectrometry-based metabolomics as a tool for discovery. The specificity of the 
novel methods outlined will be highly beneficial for compound identification and further 
confirmation of disease biomarkers. 
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Metabolomics in chronic lung diseases: a practical review for clinicians 
 
Adapted from Nambiar, S.; Bong, S. H.; Gummer, J. P. A.; Trengove, R. D. and 
Moodley, Y. (2018) “Metabolomics in chronic lung diseases” Accepted in Respirology 
 
1.1 Abstract 
 
Chronic lung diseases represent a significant global burden. Their increasing incidence 
and complexity render a comprehensive, multidisciplinary, and personalized approach 
to each patient, critically important. Most recently, unique biochemical pathways and 
disease markers have been identified through large-scale metabolomics studies. 
Metabolomics is the study of metabolic pathways and the measurement of unique 
biomolecules in a living system. Analysing samples from different compartments such 
as broncho-alveolar lavage fluid (BALF) and plasma has proven useful for the 
characterization of a number of pathological conditions and offers promise as a clinical 
tool. For example, several studies using mass spectrometry (MS) have shown alterations 
in the sphingolipid metabolism of chronic obstructive pulmonary disorder (COPD)-
sufferers. In this article, we present a practical review of the application of 
metabolomics to the study of chronic lung diseases; COPD, idiopathic pulmonary 
fibrosis (IPF) and asthma. The insights, which the analytical strategies employed in 
metabolomics, have provided to the dissection of the biochemistry of chronic lung 
diseases and future clinical biomarkers are explored. 
 
Keywords: metabolomics, lung, COPD, asthma, IPF 
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1.2 Introduction 
 
Chronic lung diseases are complex, progressive disorders with increasing incidence and 
mortality (Papaioannou et al., 2017). Chronic obstructive pulmonary disease (COPD), 
asthma and pulmonary fibrosis are examples of chronic lung conditions that can 
significantly impact the quality of life (Papaioannou et al., 2017; Zhao et al., 2018). The 
management of such conditions can be greatly enhanced using personalized approaches 
to direct treatment. There is growing evidence to support the role of metabolic 
dysfunction in the pathogenesis of chronic lung diseases (Kao et al., 2012; 
Karampitsakos and Gourgoulianis, 2016; Kang et al., 2016) and clinicians are now 
incorporating metabolomics as part of a holistic approach in disease diagnosis and 
prognosis.  
 
The earliest diagnoses of these diseases is achieved by integrating information derived 
from multiple sources including clinical assessment, radiology and pulmonary function 
tests (Flaherty et al., 2007; Jo et al., 2016). Histological assessment generally requires 
surgical biopsy, but this is impractical for all patients (Semendyayeva et al., 2017). 
Minimally-invasive diagnostic methods that eliminate bronchoscopic and surgical 
biopsy in patients are ideal; metabolomics therefore holds considerable promise for the 
discovery of biomarkers that can aid diagnosis and treatment with greater sensitivity, 
specificity and precision. 
 
In this review, we provide an overview of how metabolomics has been used to further 
the understanding of chronic lung diseases, as well as present some of the metabolic 
pathways that have been investigated in COPD, asthma and idiopathic pulmonary 
fibrosis (IPF). This manuscript builds on the existing work of Papaioannou et al. (2017) 
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and Zhao et al. (2018) who reviewed global metabolic changes in patients with chronic 
lung disease. In addition to a critical assessment of published outcomes, our review 
seeks to examine the experimental approaches and instrumental parameters used in 
these studies, as well as provide some insight into the emerging trends of metabolomics-
driven biomarker discovery. We anticipate that readers gain a practical understanding of 
current and emerging metabolomics approaches applicable to lung disease 
metabolomics and use the information presented to deliver robust metabolomics 
experimental designs that result in new insight and ultimately enhanced clinical 
decision-making. 
 
1.3 Metabolic pathways implicated in chronic lung diseases 
 
1.3.1 Cellular energetics 
 
Cellular energetics are important for the maintenance of lung cell function under various 
patho-physiological conditions. Metabolic homeostasis is vital in regulating cell 
proliferation and differentiation, and studies have shown that metabolic dysregulation 
contributes to various inflammatory responses and apoptosis (King, 2015; Kumar et al., 
2017). The catabolism of major nutrient substrates such as sugars, amino acids and fatty 
acids (FAs) introduces acetyl-CoA into the tricarboxylic acid (TCA) cycle to produce 
metabolites for the synthesis of nucleotides, proteins and lipids, and most importantly to 
generate energy. These cellular processes have been implicated in disease pathogenesis; 
however, the roles of these metabolic dysregulations and the underlying disease 
mechanisms are not fully understood (Zhao et al., 2018). Figure 1 illustrates the 
metabolic intermediates involved in cellular energetics and the pathways involved in 
chronic lung diseases. 
 Chapter 1 
 
4 
 
1.3.1.1 Glycolysis and TCA cycle 
 
Glycolytic dysregulation is well-defined in lung diseases such as lung cancer (Maher, 
2015). Glycolysis is an oxygen-independent metabolic pathway that converts glucose 
into pyruvate through a 10-step biochemical reaction to produce adenosine triphosphate 
(ATP). The three main enzymatic reactions responsible for the control of glycolytic flux 
are catalysed by hexokinase, phosphofructokinase and pyruvate kinase (Hasawi et al., 
2014; Sreedhar and Zhao, 2018). Under aerobic conditions, pyruvate is commonly 
transported into mitochondria and converted to acetyl-CoA. Acetyl-CoA, which is 
derived via beta-oxidation, enters the TCA cycle to produce nicotinamide adenine 
dinucleotide (NADH) and flavin adenine dinucleotide (FADH2), the electron carriers 
that donate electrons to the electron transport chain. This subsequently leads to ATP 
generation (Koppenol et al., 2011; Sreedhar and Zhao, 2018). Regulation of the TCA 
cycle is heavily dependent on the availability of enzyme-substrates. Malate is one of the 
TCA cycle intermediates exported from the mitochondria to the cytosol, where malic 
enzyme can then regenerate NADH and pyruvate from malate for cycling back into the 
mitochondria (Hanse et al., 2017). Like malate, citrate can also cross from the 
mitochondrial membrane to the cytosol, where it is cleaved by ATP citrate lyase to 
produce cytosolic acetyl-CoA (Ren et al., 2017) for FA synthesis. Glycolytic energy 
dysregulation in lung cancer cells has been reported to cause uncontrolled proliferation 
as cells strive to meet demand for non-essential amino acids and FAs. Glutamine 
consumption, in addition to glucose, is significantly increased in diseased cells, 
resulting in its metabolism to alanine, lactate, with an increased production of 
ammonium ion by-products (Li et al., 2015). Glycolytic hyperactivity followed by lactic 
acid fermentation, as opposed to steady-state glycolysis followed by pyruvate oxidation, 
is a hallmark of lung cancer metabolism and is known as the Warburg effect (Warburg 
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et al., 1927; Gatenby and Gillies, 2004). The exact mechanism of this “aerobic 
glycolysis” remains unclear; it has been suggested that cellular proliferation and 
extracellular matrix production are the results of this glycolytic change (Maher, 2015). 
 Chapter 1 
 
6 
 
 
Figure 1.1 An illustration of the metabolic pathways involved in cellular energetics: yellow, blue and red zones correspond to pathways affected in 
COPD, asthma and IPF, respectively. Sections in green (COPD and IPF) and purple (asthma and IPF) illustrates overlapping pathways in the 
aforementioned diseases.
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1.3.1.2 Mitochondrial-beta oxidation and fatty acid metabolism 
 
The lungs exist in an environment of elevated oxygen. The large surface area and high 
blood supply make this organ highly susceptible to injuries mediated by oxidative stress. 
Exogenous exposure to reactive oxygen species (ROS) such as NO2, SO2, CO, and dust 
particles, as well as cigarette smoke, can lead to excessive oxidative stress and trigger 
inflammatory responses of the lung tissue (Guarnieri and Balmes, 2014). Mitochondrial 
oxidative phosphorylation can also contribute to ROS exposure and may exacerbate 
pathology. While mitochondria-derived functions (for e.g. ATP production, cellular 
signalling and differentiation, cell cycle regulation and cell growth) are efficient 
processes, high-energy electrons are released from the respiratory chain and can form 
ROS (Bartlett and Eaton, 2004). This was believed to result in mitochondrial oxidative 
stress and promote degenerative pathology (Vazquez et al., 2015).  
 
Regulation of beta-oxidation and the relationship between FA metabolism and 
carbohydrate metabolism was defined in the early 80s (McGarry and Foster, 1980). 
Fatty acid oxidation to acetyl-CoA is well studied and it has been suggested that the 
enzymes of beta-oxidation are organized into a multi-enzyme complex (Bartlett and 
Eaton, 2004). Most saturated FAs are catabolized by mitochondrial beta-oxidation, 
providing acetyl-CoA as a substrate for the TCA cycle. Through FA oxidation, ATPs 
are produced; however, this is often accompanied by ROS.  
 
1.3.1.3 Lipid metabolism  
 
Lipid metabolism plays a key role in the lung, resulting in the synthesis and oxidation of 
FAs, lipid esterification, hydrolysis of lipoproteins, synthesis of phosphatidylcholine, 
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and synthesis and secretion of prostaglandins and other eicosanoids from arachidonic 
acid precursors (Yan et al., 2017; Merino Salvador et al., 2017). The abnormal 
lipid/metabolic phenotype of COPD, asthma and IPF have been reported by the work of 
Teichgraber et al. (2008), Yang and Uhlig (2011) and Ley et al. (2014) who highlighted 
a key role for lipid metabolism in lung diseases. 
 
The oxidation of FAs during lipid metabolism also plays an important role in regulating 
glycolysis. Subsequent steps in FA synthesis is the production of palmitate, a primary 
FA that can undergo various elongation or unsaturation cycles to yield other FA 
molecules. FAs need to be activated with CoA by fatty acyl-CoA synthetases which is 
critical for phospholipid and triglyceride synthesis (Yan et al., 2017). These lipids are 
fundamental component of cellular membranes, play critical roles in cellular functions 
including energy storage, signal transduction, formation of membrane bilayer and 
cellular barriers. Hence, dysregulated FA oxidation can disrupt lipid metabolism that 
contributes to various pathological features. 
 
The dysregulation of lipid metabolism has been well-described in Alzheimer’s disease, 
diabetes, obesity, atherosclerosis and in several lung diseases such as cystic fibrosis, 
asthma and COPD (Yan et al., 2017). In the proliferating cell, there is an increase in the 
uptake of exogenous FA due to an increase in adipogenesis (Bartlett and Eaton, 2004; 
Merino Salvador et al., 2017). 
 
1.4 Metabolomics- an emerging ‘omic modality for clinical research  
 
Metabolomics is generally applied through a targeted, selective measurement strategy, 
or as part of an untargeted, global profiling approach (Wilson, 2017; Bowler et al., 
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2017; Bingol, 2018). Targeted metabolomics is a quantitative approach that allows for 
the measurement of metabolite concentrations while untargeted metabolomics 
undertakes simultaneous assessment of metabolites without any prior sample knowledge 
for hypothesis generation (Bingol, 2018). Untargeted metabolomics is a comprehensive 
strategy for identifying changes in different patho-physiological states (Wang et al., 
2010); however, a major disadvantage is that the majority of features are unidentifiable. 
Feature identification can be improved by using sophisticated data-independent 
acquisition techniques,  which will additionally collect important structural detail in the 
metabolite measurements for interpretation at a later date without the need for re-
measurement of samples (Gethings et al., 2017) since accurate mass measurement alone 
is insufficient for compound identification (Wang et al., 2010; Bingol, 2018). 
Additional orthogonal information, such as chromatographic retention time, tandem MS 
fragmentation (MS/MS), isotopic patterns and collisional cross-section, are also 
necessary for structural annotation and compound identification (Wang et al., 2010; 
Bingol, 2018). Advents in analytical technologies and bioinformatics are setting the 
stage for large-scale, harmonized metabolic profiling suitable for studies at the 
population level (Wilson, 2017). Metabolic phenotyping considers the total metabolite 
profile as a unique pattern, or fingerprint, for a specific pathological state without 
attempting to identify all the features present in the profile. 
 
Confirmatory diagnoses of lung diseases are heavily dependent on the application of 
high-resolution computed tomography and surgical biopsies (Flaherty et al., 2004; 
Elicker et al., 2008; Kaarteenaho, 2013). While surgical biopsy is still regarded as the 
gold standard, diagnostic misinterpretations has been documented (Kaarteenaho, 2013). 
Lin et al. (2014) suggested the application of metabolomics as a clinical tool to support 
disease diagnostics. Untargeted metabolomics can be useful for clinical research as it 
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provides practitioners with a systemic approach to understand global changes in 
response to an alteration in nutrition, genetics, environment and gut microbiota 
(Griffiths et al., 2010). It also allows for the interrogation of endogenous biochemicals 
involved in key metabolic processes and provides novel insights into the molecular 
mechanisms associated with an alteration or perturbation of the physiological status 
(Zhang et al., 2010). Despite the heterogeneity associated with pulmonary diseases, 
metabolomics is particularly useful for endotyping and phenotyping, and promises to 
stratify individuals based on severity and exacerbation as well as enhance the diagnostic 
accuracy of diseases such as COPD (Comhair et al., 2015; Adamko et al., 2015). 
 
1.5 Analytical techniques in metabolomics 
 
This review will focus on information rich analytical techniques such as nuclear 
magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) that are routinely 
used for metabolomics research (Gowda et al., 2008). 
 
1.5.1 NMR spectroscopy 
 
NMR is widely used due its ability to simultaneously measure multiple metabolites 
within a short acquisition time and with minimal preparation (Stringer et al., 2016; 
Markley et al., 2017). As a non-destructive technique, NMR is highly advantageous as 
the samples can be re-used for multiple assays. This is especially important where 
sample amount is limited, which is common in clinical settings. The major limitation of 
NMR for metabolomics is its low sensitivity, which results in micromolar detection 
levels (Gowda and Raftery, 2015). Depending on the nature of the sample and 
experimental hypotheses, a number of NMR techniques are applied in metabolomics. 
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1H-NMR is the most commonly used NMR technique for metabolic phenotyping and 
biomarker discovery due to its simplicity, robustness and repeatability (Wilson, 2017), 
followed by 31P-NMR and 13C-NMR (Wang et al., 2010; Gowda and Raftery, 2015). 
NMR has been used to study the metabolome of lung diseases, including silicosis (Hu et 
al., 2008), asthma and COPD (Adamko et al., 2015) and respiratory syncytial viral 
infection (Adamko et al., 2016). One-dimensional (1D) 1H NMR suffers from low 
spectral resolution which limits metabolome coverage and accuracy of metabolite 
analysis (Bingol, 2018). Current NMR developments are focused on reducing spectral 
overlap. For example, two-dimensional (2D) NMR experiments have been used to 
improve resolution and sensitivity. However, the main limitation of 2D NMR is its 
longer method acquisition.  
 
1.5.2 Mass spectrometry 
 
MS-based metabolomics provide increased sensitivity and selectivity for measuring a 
range of cellular metabolites in various biological samples (Gowda and Raftery, 2015). 
MS-based metabolic profiling can also be performed using a shotgun approach based on 
direct infusion MS (Wilson, 2017) or in combination with a number of front-end 
chromatographic separation techniques (Stringer et al., 2016). 
 
Liquid chromatography (LC)-MS is the analytical approach most often used for 
metabolomics due to its ability to resolve different classes of metabolites (Wang et al., 
2010; Stringer et al., 2016). Some of the advantages of LC-MS based metabolomics are: 
1) good coverage of mass ranges, which permits the detection of metabolites with 
different chemical properties, 2) no requirement for sample derivatization and 3) high 
sensitivity at nanomolar levels (Stringer et al., 2016). Aqueous metabolites can also be 
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simultaneously assayed and recent advances are now enabling greater separation and 
detection of metabolites such as lipids. The disadvantages of LC-MS include its high 
variability across different instruments, the lack of standardized metabolite libraries as 
well as the numerous standard preparative steps and data processing workflows 
(Stringer et al., 2016). 
 
An important consideration for LC-MS based metabolomics is the type of 
chromatography column used as this determines the class of metabolites for separation. 
The polarity and pH of the solvents also influences metabolite separation (Stringer et al., 
2016). Reverse-phase columns such as C18 columns provide good retention and 
separation of non-polar compounds (Wang et al., 2010). Alternatively, hydrophilic 
interaction chromatography (HILIC) columns are preferred for the detection of polar 
compounds (Wilson, 2017). Electrospray ionization (ESI) is the preferred ion source for 
coupling LC with MS for metabolomics studies as it provides coverage of both positive 
and negative ions (Stringer et al., 2016).   
 
Quadrupole, time-of-flight (TOF) and ion traps are some of the more commonly used 
mass analyzers coupled to LC separation (Wang et al., 2010). Triple quadrupole (QQQ) 
analyzers, allow for tandem MS experiments (MS/MS) or further fragmentation of ions 
during analysis. Similarly, ion trap analyzers trap ions of interest and accumulate them 
for better sensitivity (Stringer et al., 2016). They can also trap and fragment a specific 
ion multiple times (MSn) to allow detection of selective ions (Stringer et al., 2016). In 
contrast, TOF analyzers determine the m/z by accelerating ions and then measure the 
time required to traverse a flight tube. TOF analyzers have increased mass accuracy and 
are highly sensitive (Wang et al., 2010). They can be coupled with a quadrupole (Q-
TOF; Wang et al., 2010), which is well suited for metabolite detection. Fourier 
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transform ion cyclotron resonance (FT-ICR) paired with MS detectors have the highest 
degree of mass accuracy and have MS/MS and MSn capabilities but are limited by high 
costs (Wang et al., 2010; Stringer et al., 2016). 
 
The advantages of gas chromatography (GC)-MS include high sensitive and specific for 
the separation and detection of volatile metabolites (Wang et al., 2010; Wilson, 2017). 
In addition, spectral patterns and retention times of compounds are highly reproducible 
(Stringer et al., 2016), and allows for the use of established compound libraries such as 
the National Institute of Standards and Technology (NIST) Mass Spectral Library. 
There is also lower instrument-to-instrument variability, which is a limitation of LC-MS. 
However, GC-MS based metabolomics is usually reserved for thermally stable volatile 
compounds that are of low polarity (Wang et al., 2010) and those that are amenable to 
derivatization (Wilson, 2017). GC derivatization can lead to a loss of metabolites while 
incomplete derivatization can result in spectral artifacts. 
 
1.6 Metabolomics-driven discovery of biomarkers 
 
Towards the discovery of biomarkers and in the pursuit of improved disease 
characterisation, metabolomics has been employed for the study of lung diseases to 
study a large number of sample types including urine (Adamko et al., 2016), plasma and 
serum (Kumar et al., 2017), cerebrospinal fluid (Locasale et al., 2012), exhaled breath 
condensate (EBC; Fermier et al., 2016), bronchoalveolar lavage fluid (BALF; 
Cruickshank-Quinn et al., 2017), saliva (Barnes et al., 2014), intact tissue (Hu et al., 
2008) as well as cells (Luo and Li, 2017) and their extracts. Urine and blood are the 
most commonly used biofluids for metabolomics studies as both samples contain 
thousands of detectable metabolic features and can be collected using minimally 
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invasive methods. Table 1.1 below provides an analysis of recent metabolomics studies 
of COPD, asthma and IPF and provide a summary of each study according to the 
metabolic pathways implicated, samples type assayed, and the analytical techniques 
utilized. 
 Chapter 1 
 
15 
 
Table 1.1 Summary of recent metabolomics studies reporting the metabolic pathways associated with COPD, asthma and IPF, samples assessed, 
and analytical techniques used. Ionisation modes are described as positive (+) and/or negative (-) electrospray (ESI) or electron impact (EI) 
while MS/MS and 1D-1H and stands for tandem MS technique and one-dimensional proton NMR experiment, respectively. HILIC is abbreviated 
for hydrophilic interaction chromatography and RP denotes reversed-phase chromatography. 
 
Disease Investigators Sample Separation (method) MS (ionisation mode) Metabolic pathways 
 
 
 
 
COPD 
Kilk et al. (2018) EBC, 
serum 
LC (direct injection) MS (+ and - ESI) Sphingolipid metabolism 
Arginine metabolism 
Naz et al. (2017) Plasma, 
BALF 
LC (HILIC and RP) 
 
MS (+ and - ESI) TCA-cycle  
Glycerophospholipid metabolism 
Fatty acid metabolism  
Sphingolipid metabolism 
Adamko et al. (2015) Urine NMR (600 MHz) 1D-1H Nitric oxide pathway  
Coenzyme A biosynthesis 
 
 
 
 
Asthma 
Carraro et al. (2018) Urine LC (RP) MS (+ and - ESI) Tryptophan metabolism  
Fatty acid metabolism 
Reinke et al. (2017) Serum LC (HILIC and RP) MS (+ and - ESI) Sphingolipid metabolism 
Fatty acid metabolism 
Eicosanoid metabolism 
McGeachie et al. (2015) Plasma LC (RP) MS (+ ESI) Linoleic acid metabolism 
Arachidonic acid metabolism 
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Sphingolipid metabolism 
Fatty acid metabolism 
Taurine metabolism 
 
 
 
 
IPF 
Rindlisbacher et al. (2018) Serum LC (RP) MSE (+ and - ESI) Lysophosphatidic acid metabolism 
Zhao et al. (2017) Lung 
tissue 
LC  
GC 
MS/MS 
MS 
Sphingolipid metabolism 
Arginine metabolism 
Glycolysis  
Mitochondrial beta-oxidation  
TCA-cycle 
Kang et al. (2016) Lung 
tissue 
GC MS (EI) Glycolysis  
Glutathione biosynthesis 
Ornithine aminotransferase 
metabolism 
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In the past decade, improvements in high-throughput analytical technologies has 
allowed for a broader coverage of the metabolome and consequently, increased its 
utilization in biomarker discovery (Griffiths et al., 2010; Wilson, 2017). Biomarkers are 
classified as screening, diagnostic, or prognostic chemical markers based on their ability 
to predict, diagnose or evaluate the condition of a disease, respectively (Biomarkers 
Definitions Working Group, 2001; Fleming and Powers, 2012). Metabolomics-driven 
biomarker discovery is focused on the elucidation of patho-physiological mechanisms, 
with the ultimate objective of carrying out more accurate diagnosis and personalized 
treatment from an informed perspective (Griffiths et al., 2010). Table 1.2 below 
provides a list of published candidate biomarkers of chronic lung diseases grouped 
according to the metabolic pathways reviewed in this paper. 
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Table 1.2 Putative and candidate biomarkers of chronic lung diseases correlating to the 
glycolytic and TCA-cycle, mitochondrial beta-oxidation, fatty acid as well as lipid 
metabolism pathways. 
 
Metabolic 
pathways 
Putative biomarkers References 
Glycolysis & 
TCA-cycle 
glucose 
pyruvate 
hexokinase 
acetyl-CoA 
NADH 
FADH2 
malate 
citrate 
glutamine  
alanine 
lactate 
 
aspartate 
arginine 
myoinositol 
fumarate 
adenosine 
succinate 
threonine 
α-ketoglutarate 
pyruvate kinase  
phophofructokinase  
Hasawi et al. (2014) 
Ren et al. (2017) 
Bowler et al. (2017) 
Sreedhar and Zhao 
(2018) 
Mitochondrial-beta 
oxidation & fatty 
acid metabolism 
carnitine 
acylcarnitine 
choline 
citrate 
acyl-CoA 
acetate 
acetyl-CoA 
threonine 
linoleic acid 
palmitate  
malate 
serine  
eicosanoids  
arachidonic acid 
lysophosphatidic 
acid 
 
Mehta et al. (2010) 
Conlon et al. (2015) 
Bowler et al. (2017) 
 
Lipid metabolism phospholipids 
triglycerides  
sphingolipids  
arachidonic acid 
palmitate 
betaine 
choline  
ceramides 
Teichgraber et al. 
(2008) 
Yang and Uhlig 
(2011) 
Ley et al. (2014) 
Yan et al. (2017) 
Bowler et al. (2017) 
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1.6.1 Metabolomics studies of COPD  
 
COPD is a debilitating condition affecting millions of people worldwide and is the 
leading cause of chronic morbidity and mortality in patients with lung disease (Obi et 
al., 2018). Tobacco smoking and atmospheric pollution are the main risk factors for the 
development of COPD (May and Li, 2015). It is characterized by excess mucus 
production and small airway destruction, causing reduced lung compliance. These 
pathological changes are associated with oxidative stress and inflammatory responses 
that leads to an imbalance in cellular proliferation (Fischer et al., 2011; King, 2015). 
 
A number of recent studies has revealed metabolic dysregulation in COPD patients 
(Kao et al., 2012; Adamko et al., 2015; Naz et al., 2017; Kilk et al., 2018). For example, 
alterations in the sphingolipid metabolism was identified in COPD patients (Kilk et al., 
2018) and patients in the Karolinska smoking-related disease cohort (Naz et al., 2017), 
suggesting a dysregulation of lipid metabolism during the onset of COPD. This was 
further supported by the findings of Adamko et al. (2015) who identified an increase in 
betaine and choline levels in COPD patients. Both betaine and choline play important 
roles in methyl group metabolism and in the synthesis of membrane phospholipids 
(Lever and Slow, 2010). These studies also support a hypothesis of FA oxidation and 
tryptophan metabolism dysregulation leading to a state of high oxidative stress. An 
effect on FA oxidation was also demonstrated in COPD participants by Naz et al. 
(2017) who measured the ratio of carnitine and acylcarnitine using tandem LC-MS. The 
study found that the ratios between the medium and long-chain carnitines were 
significantly lower in the COPD samples compared to the healthy controls. 
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Altered FA oxidation due to reduced levels of free carnitine in lung tissue have also 
been implicated in progressive emphysema (Conlon et al., 2015) and COPD (Naz et al., 
2017). Smoke exposure has been shown to increase FA oxidation through reduced 
levels of circulating polyunsaturated fatty acids (PUFA) along with other inflammatory 
processes (Puri et al., 2008; Carraro et al., 2018). Baldassarre et al. (2014) outlined the 
mechanism of smoking-induced changes of plasma FAs that consequently enhanced 
peroxidative processes. It has been postulated that an increase in smoke exposure 
increases FA levels in cellular cytosol, resulting in protection against lipotoxicity. 
Conversely, impaired carnitine metabolism in COPD can cause accumulation of FA in 
the cytosol which can also lead to lipotoxicity (Baldassarre et al., 2014; Adeva-Andany 
et al., 2018). Metabolomics in COPD provides insight into the pathogenesis of the 
disease with alterations in sphingolipid metabolism and changes in lipids during 
increased oxidant stress. 
 
1.6.2 Metabolomics studies of Asthma  
 
Asthma is one of the most common chronic lung diseases of children and is caused by a 
range of inflammatory mechanisms (Reinke et al., 2017). It is typically characterised by 
shortness of breath or episodic wheeze due to airway obstruction resulting from various 
stimuli (Aziz-Ur-Rehman et al., 2017). In asthma, the symptoms of systemic 
inflammation are less prevalent than in COPD (Athanazio, 2012; Hawken et al., 2018).  
 
Recent studies by McGeachie et al., (2015), Reinke et al. (2017) and Carraro et al. 
(2018) examined inflammatory pathways consequent to lipid and amino acids 
dysregulation. McGeachie et al. (2015) used LC-MS in positive ion mode to reveal 
increased levels of taurine and glycine in children aged between one to 18 years with 
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asthma. This observation was supported by Reinke et al. (2017). Taurine and glycine 
has been shown to regulate cytokine overexpression in allergies (McGeachie et al., 
2015) and has protective effects.  Arginine, like taurine, is also strongly induced by T-
helper cytokines such as interleukin (IL)-4 and IL-13. Interestingly, lipid mediators are 
important in inflammatory responses and have well-defined roles in T-cell recruitment. 
The elevated levels of linoleic and oleic acids reported by McGeachie et al. (2015) is 
consistent with the enrichment of linoleic acid metabolism which further underpin their 
involvement in asthma pathogenesis. The role of oxidative stress in asthma has also 
been well-characterized and suggested that imbalances between oxidation and reducing 
systems can contribute to the disease state.  
 
Both endogenous and exogenous ROS including superoxide and reactive nitrogen and 
hydrogen species increase airway inflammation and are key determinants of asthma 
severity (Mehta et al., 2010). Choline therapy has been shown to reduce inflammation 
and supress oxidative stress in patients with asthma (Mehta et al., 2010). An increased 
level of choline may potentially cause an adaptive response in the lungs by depleting 
other lipid metabolites. Ried et al. (2013) showed that asthmatic patients have 
significantly lower levels of phosphatidylcholine (PC) in lung surfactant, which can lead 
to reduced lung function. Metabolomics increasingly demonstrates how inflammation of 
asthma is modified by metabolomes thus providing future therapeutic targets. 
 
1.6.3 Metabolomics studies of IPF  
 
Idiopathic pulmonary fibrosis is a chronic, progressive lung disease characterized by 
alveolar epithelial cell damage, proliferation of fibroblasts, and extracellular matrix 
accumulation leading to irreversible distortion of the lung architecture (Kang et al., 
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2016). The aetiological causes of IPF remain unknown to date. While genetic and 
metabolic determinants associated with the development of fibroses have been reported 
by Gangwar et al. (2017) and Zhao et al. (2017), the underlying disease 
pathophysiology remains unclear. 
 
Metabolic profiling studies conducted by Zhao et al. (2017) used both GC and LC-MS 
to demonstrate the abnormalities in metabolic pathways including glycolysis, 
mitochondrial β-oxidation, TCA cycle and sphingolipid metabolism in association with 
IPF. Xie et al. (2015) showed that the inhibition of glycolysis via 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 3 (PFKFB3) protects against the development of lung 
fibrosis in mice by using similar analytical platforms. Kang et al. (2016) and Zhao et al. 
(2017) applied a range of untargeted and targeted methods to study accelerated 
glycolysis in the IPF lung. The results suggested that glycolysis plays a role in the 
fibrotic phenotype. This is consistent with the observation that an increased rate of 
glycolysis can cause increased glycine biosynthesis, resulting in its incorporation into 
collagen, a process central to lung fibrogenesis (Hamanka et al., 2018). 
 
Hamanaka et al. (2018) reported that transforming growth factor (TGF)-β promoted 
fibrogenesis which included the expression of serine and glycine synthesis pathway in 
human lung fibroblasts. As TGF-β1 increases both glycolysis and oxidative 
phosphorylation, the roles of glucose, glutamine, and fatty acid oxidation during TGF-β 
mediated fibrosis warrant further investigation. Rindlisbacher et al. (2018) used RP 
separation followed by an exploratory, high resolution, MSE method to measure 
increased levels of lysophosphatidylcholine (LysoPC) and 3-hydroxydecanoyl carnitine 
in IPF patients. Lysophosphatidylcholine is a precursor of Lysophosphatidic acid (LPA), 
a FA that induces epithelial cell damage, inflammation and fibrosis in kidney (Sakai et 
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al., 2017) and liver (Kaffe et al., 2017). The downregulation of glycolysis, 
mitochondrial beta-oxidation and TCA pathways suggested that alternative energy 
pathways have been upregulated to support lung remodelling (Zhao et al., 2017). The 
changes in lipids in IPF may in future provide insights into intracellular changes that 
occur in this progressive condition. This may improve treatments in the future. 
 
1.7 Frontiers in metabolomic analysis of chronic lung diseases 
 
Clinical metabolomics applications are presently dominated by the use of tandem MS 
platforms. These instruments are mainly used for targeted analysis of specific 
metabolites or metabolite classes such as amino acids, neurotransmitters, steroids and 
drugs (Jannetto and Fitzgerald, 2016). While technological advancements continue to 
broaden the metabolite coverage afforded by high resolution analytical instruments such 
as QTOF-MS, considerable challenges remain in data interrogation and the validation of 
metabolite identities (Bowler et al., 2017). Efforts to improve, and augment, the 
metabolomics data pipeline are currently focused on biostatistical and bioinformatics 
approaches, new resources for biochemical pathway mapping, enrichment analyses and 
even the application of machine learning principles. It is, nevertheless, well established 
that joint efforts are needed to promote data sharing, method synchrony and sample 
storage integrity, because the novelty of metabolomics methodologies and laboratory-
specific practices are highly influential to the comparability of metabolomics datasets 
across studies.     
 
This section of the review endeavours to present cutting-edge tools available for the 
metabolomics interrogation of lung diseases. In particular, the application of mass 
spectrometry imaging (MSI) techniques is of great interest due to its ability to provide 
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spatial information on metabolite distribution within tissue samples. MSI techniques 
such as matrix-assisted laser desorption/ionisation (MALDI; Caprioli et al., 1997) and 
desorption electrospray ionization (DESI; Takáts et al., 2004) show promise and offers 
investigators a means of chemically mapping samples without the requirement for 
specific staining or labelling agents (Rabinovich et al., 2012). A major advantage of 
MSI lies in its ability to measure changes in markers that can be directly correlated to 
morphological features of interest, abrogating the need for time-consuming techniques 
such as laser capture micro-dissection (Mirnezami et al., 2014). Carter et al. (2016) and 
Brioude et al. (2016) have successfully used MSI to characterize region-specific protein 
or peptide distribution within tissue sections. More recently, Matsumoto et al. (2017) 
used MSI to examine the localisation and distribution of therapeutic compounds in lung 
tissue samples; this presents clinicians with the opportunity to investigate therapeutic 
drug efficacy from an entirely novel perspective.  
 
While MALDI-MSI is effective for the study of molecules at the upper end of the mass 
spectrum, such as proteins and peptides (Mirnezami et al., 2014), its success profiling 
metabolites at the lower end of the mass range (<1000 m/z) is still advancing (Miura et 
al., 2012). The DESI approach developed by Takáts et al. (2004) may be more suitable 
for metabolomics studies as ionization occurs under ambient conditions and can provide 
improved resolution of lower m/z value molecular species. The application of MSI to 
complement histopathology for the visualisation of metabolites is a promising avenue 
for studies into chronic lung conditions, where such applications are yet to be applied 
outside of pulmonary diseases such as lung cancer.  
 
Metabolomics provides complementary insight into disease pathogenesis alongside the 
measurements of transciptomics and proteomics. Metabolomics can uniquely provide 
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detail of perturbations in fundamental biochemical pathways or mechanisms, such as 
TCA cycle and oxidant metabolism, or the identification of novel and as-yet 
undescribed biochemical processes. The great strength of metabolomics data however is 
in its interpretation. Whilst many thousands of features representing metabolism can be 
measured in any given metabolomics analysis, the unambiguous assignment of chemical 
identity continues to slow interpretative progress. Efforts of data mining and reduction, 
which allow resources to quickly channel toward the most relevant metabolite entities 
for ongoing validation, are integral to study translation. 
 
1.8 Conclusion 
 
For clinical studies, moving from exploratory metabolomics to a biochemical 
understanding, and ultimately improving patient outcomes, can only be achieved by 
strict experimental design and the fastidious collection of complementary phenotypic 
data; including but not limited to, extensive patient observations and prognoses, and 
wherever can be afforded, other functional diagnostic measurements including existing 
pathology markers and further exploratory ‘omics analyses. The extensive cataloguing 
of such metadata remains a challenge, however as the technology continues to advance 
and metabolomics data become increasingly information-rich, clinical outcomes will 
also improve, but only if the means to interpret the measurements are also considered. 
Chronic lung diseases such as COPD, asthma and IPF constitute some of the most 
common pulmonary disorders and are major causes of mortality worldwide. These 
diseases of the lung are highly heterogenous and remain difficult to define in a clinical 
context. The inherent complexity of these disease phenotypes pose difficulties for 
accurate diagnosis and prognosis, and as such expanding on the currently adopted 
diagnostic and prognostic tools by inclusion of data-rich metabolomics measurements 
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will provide new angles of discovery and insight. Here we have highlighted some of the 
major metabolic pathways perturbed in chronic lung diseases as well as provide an 
overview of the techniques commonly used for discovery metabolomics. As one of the 
most rapidly advancing fields in post-genomics research, metabolomics is a promising 
discovery tool that can facilitate a greater understanding of chronic lung diseases at the 
phenotypic level, and ultimately lead to the development of personalized approaches in 
patient diagnosis and treatment. 
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Untargeted metabolomics of human plasma reveal unique lipid markers in COPD 
and IPF patients 
 
Adapted from Nambiar, S.; Bong, S. H.; Rawlinson, C.; Gummer, J. P. A.; Moodley, 
Y.; and Trengove, R. D. (2018) “Untargeted metabolomics of human plasma reveal 
unique lipid markers in COPD and IPF patients” Ready for submission to Respiratory 
Medicine 
 
2.1 Abstract 
 
New paradigms have been proposed to describe similarities in the pathogenesis of 
chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) 
despite their clinical, radiological and pathological differences. Here, we applied an 
untargeted metabolomics approach to profile plasma samples from patients with COPD 
and IPF compared to samples from healthy subjects. The study successfully identified a 
number of metabolites, particularly lipid constituents which may be indicative of shared 
responses of these diseases to environmental stress. A total of 65 individual plasma 
samples were analysed, 21 of which were from patients diagnosed with COPD, 24 from 
IPF and 20 from healthy control participants (HC). Untargeted metabolomics profiling 
was performed using an ultra-high performance liquid chromatography-quadrupole 
time-of-flight mass spectrometer (UHPLC-QTOF-MS) equipped with a C18 column in 
positive ion acquisition mode. Non-polar metabolites such as fatty acids and membrane 
lipids were well-resolved using the reversed-phase method and a total of 4,805 features 
(chromatographic peaks with specific retention time and mass-to-charge ratio) were 
identified following data normalisation, quality control corrections, and applications of 
dimensionality reduction techniques such as principal component (PCA) and orthogonal 
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projections to latent structures discriminant analyses (OPLS-DA). Multivariate statistics 
performed using both Progenesis QI and EZinfo software packages showed distinct 
separation between COPD and IPF compared to the healthy controls and the most 
significant features were identified using multiple database matching. Differences in 
metabolite compositions such as lipid mediators, bilirubin and dihydrotestosterone were 
observed between diseased and control groups, as well as within COPD and IPF 
diseased groups. 
 
Keywords: metabolomics, lung, plasma, COPD, IPF 
 
2.2 Introduction 
 
Chronic lung diseases are complex diseases that affect a significant portion of the 
population with increasing incidence and mortality (Papaioannou et al., 2018). COPD, a 
smoking-induced lung disease, accounts for the majority of chronic lung disease 
mortalities, while more than 15,000 deaths per year are attributed to idiopathic 
pulmonary fibrosis (Kusko et al., 2016). COPD is defined as a disease state 
characterized by exposure to a noxious agent such as cigarette smoke-induced with 
airflow limitation resulting from infiltration of inflammatory cells (Lin and Jiang, 2015; 
Naz et al., 2017). Patients diagnosed with COPD sustain destruction of lung elastin and 
other extracellular matrix proteins, increased alveolar cells apoptosis, and cellular repair 
that leads to airspace enlargement characteristic of emphysema (Kusko et al., 2016). 
IPF, on the other hand, is characterized by a pattern of ‘usual interstitial pneumonia’ 
(Chilosi et al., 2012), including active fibroblast proliferation associated with minimal 
inflammation, extracellular matrix deposition, and abnormal alveolar remodelling 
(Kusko et al., 2016; Papaioannou et al., 2018). There is growing evidence to support the 
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role of metabolic dysregulation in the pathogenesis of COPD and IPF. Metabolomics 
can provide the means to study such changes and can potentially identify biomarkers to 
improve disease diagnosis and treatment.  
 
The fundamental aim of metabolomics is to identify the changes in metabolite 
composition associated with physiological or pathological change. Both lung conditions 
are highly heterogeneous, and the lack of diagnostic and predictive biomarkers has 
hindered new therapeutic interventions and the implementation of precision treatment. 
Studies by Reinke et al. (2017) and Maniscalco et al. (2018) has demonstrated changes 
in metabolite profiles of asthma, COPD and IPF participants. These studies highlighted 
the growing appeal of using metabolomics to profile challenging lung diseases as well 
as discriminate individuals based on levels of disease severity and lung exacerbations 
(Bowler et al., 2017). Recent metabolomics studies of COPD have focused on targeted 
mass spectrometry (MS) based approaches which provided absolute quantitation of 
predetermined proteins of interest (Leung et al., 2016; Niu et al., 2017; Fujii et al., 
2017). Kang et al. (2016) and Cruickshank-Quinn et al. (2017), on the other hand, used 
untargeted MS-based metabolomics to profile changes in the lung tissue and plasma of 
IPF and COPD patients and showed changes in a number of biochemical pathways. 
Untargeted MS-based metabolomics generally result in greater metabolite coverage 
compared to targeted approaches.  
 
This study was based on the application of untargeted metabolomics to profile plasma 
samples derived from COPD and IPF patients. Data generation was followed by the 
application of multivariate statistics for both supervised and unsupervised approaches to 
identify putative biomarkers of interest. The identity of these compounds were then 
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elucidated by database matching using LIPID MAPS, Biomolecules, ChEBI, HMDB 
and Drug Bank.  
 
2.3 Materials and Methods 
 
2.3.1 Chemicals and Reagents 
 
UPLC-grade methanol (MeOH), acetonitrile (ACN), water (H2O) and chloroform were 
sourced from Fisher Scientific (Thermo Fisher, Australia). The internal standard d6 t-
cinnamic acid and formic acid were obtained from Sigma-Aldrich (New South Wales, 
Australia). 
 
2.3.2 Biological samples 
 
A total of 65 plasma samples were used in this study. 21 samples were obtained from 
patients diagnosed with COPD, 24 samples were obtained from IPF and 20 samples 
were obtained from healthy controls (HC). The associated demographic information 
(de-identified) was provided in Supplementary Table 2.1. The samples were stored in -
80°C until further analysis. Sample handling and experimental protocols were approved 
by the Royal Perth Hospital Human Research Ethics Committee (Reference number: 
REG 15-204). 
 
2.3.3 Sample preparation 
 
Plasma samples were prepared using a modified Bligh and Dyer extraction method. 
Once thawed on ice, samples were centrifuged (1 min, 4 °C, 16,100 x g) to pellet any 
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precipitate upon initial freezing. 100 µL of plasma was aliquoted into a new 
microcentrifuge tube to which 300 µL of MeOH (containing the internal standard d6 t-
cinnamic acid at 83.3 ng/mL) and 100 µL of chloroform were added. Samples were then 
vortexed for 10 s and incubated for 10 mins at 4 °C and 1,600 x rpm in a benchtop 
Thermomixer (Eppendorf). An additional 200 µL of H2O was added and vortexed for 
another 10 s. The samples were then incubated for an additional 10 mins at 4 °C and 
1,600 x rpm. After incubation, the precipitate was pelleted by centrifugation for 10 mins 
at 4 °C and 16,100 x g. The aqueous phase (250 µL; polar fraction) and organic layer 
(70 µL; non-polar fraction) were transferred to fresh microcentrifuge tubes by pipette. 
The organic layer was dried using a rotary vacuum concentrator for 10 mins and the 
dried sample stored at -80 °C until analysis. From the aqueous phase, the majority of 
MeOH were removed by rotary vacuum concentrator for 90 mins followed by the 
addition of 100 µL of H2O for the dilution of any remaining MeOH. Samples were 
frozen by submersion in liquid nitrogen and lyophilized to dryness before storage at  
-80 °C. Pooled samples were also generated for quality control (QC) normalization by 
aliquoting 20 µL from each sample into a single tube and extractions were carried out as 
per the above method. Blank extractions were also performed; however, plasma was 
substituted with 100 µL of H2O. 
 
2.3.4 Mass spectrometry acquisition 
 
Sample analysis was performed by ultra-high performance liquid chromatography 
quadrupole-time-of-flight mass spectrometry (UHPLC-QTOF-MS) using a Shimadzu 
Nexera LC30AD LC system coupled to a SCIEX Triple-TOF 5600 MS. The LC unit 
was equipped with a 1.7 µm Kinetex C18 (100 x 2.1 mm) column from Phenomenex, 
and chromatography achieved using mobile phase A at 0.2 % formic acid and ACN 
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(0.2 % formic acid, B) at a solvent flow rate of 300 µL/min. An isocratic composition of 
1 % B was used for the first min, with a subsequent solvent gradient increasing to 
99.5 % B over 36 mins and a 1 min hold, before returning to 1 % B at 39 mins and 
holding to 40 mins. The CTO-20A column oven (Shimadzu) was held at 35 °C. The ion 
source was operated at a temperature of 550 °C, using a positive ion spray voltage of 
5500 V; and nebulisers, heater and curtain gas pressures of 45, 50 and 30 psi, 
respectively. Data were acquired with a mass range of m/z 50 – 1,000 using an 
independent data mode of acquisition (IDA) including a sweeping collision energy of 35 
± 15. Analyst v1.5 (SCIEX) was used for instrumental control and data acquisition. Due 
to the limited amount of sample available, this study was focused on positive ion mode 
acquisition as a first pass. 
 
2.3.5 Data processing and statistical analysis 
 
The raw MS data were imported and processed with Progenesis QI (version 2.2, 
Nonlinear Dynamics, Newcastle, UK). After chromatographic alignment, ion patterns 
were deconvoluted between 1 and 36 mins of the acquisitions. Adduct ion signatures for 
[M+H]+, [M+Na]+, [M+K]+ and [M+NH4]
+ were deconvoluted from the acquired raw 
MS data in positive mode followed by normalisation of the detected features to all 
compounds. Background correction was performed by excluding ion patterns with a 
two-fold higher abundance in blank versus QC samples and a coefficient of variation of 
the peak area > 30 % in the QC samples, as recommended by Dunn et al. (2012), 
Wehrens et al. (2016) and Broadhurst et al. (2018). The normalized abundances of the 
remaining features were subjected to multivariate analysis with EZinfo (Umetrics, 
Umeå, Sweden) for identification of features of interest. The data was Pareto-scaled and 
principal component analysis (PCA) was performed to visualize trends and detect 
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outliers among observations in the scores plot. PCA was followed by orthogonal partial 
least square discriminant analysis (OPLS-DA) including model cross-validation to 
compare discriminant features between healthy controls (HC) and COPD, HC and IPF 
as well as between COPD and IPF samples. Results were further interrogated using a 
variable importance in projection (VIP)-plot to find discriminative metabolite 
candidates having a score of ≥ 1. Subsequently, each metabolite candidate was reviewed 
for its ion alignment and chromatographic peak shape. The features of interests were 
extracted from S-plots constructed following OPLS-DA analysis based on their 
contribution to the variation and correlation between the two groups. Selected features 
were interrogated against databases including LIPID MAPS, Biomolecules, Chemical 
Entities of Biological Interest (ChEBI), Drug Bank and the Human Metabolome 
Database (HMDB) at a mass accuracy of 10 ppm for metabolite structure and formula. 
 
2.4 Results and Discussion 
 
A total of 19,955 features were curated to 4,805 following data pre-processing and 
filtration. PCA was applied to obtain an overview of the variations between COPD, IPF, 
healthy and QC samples. Two different PCAs were applied to assess the changes in 
grouping by applying background correction or noise reduction. Figure 2.1 showed two 
PCA scores plot of which one was generated prior to background correction and the 
other was generated post-correction. An increased separation of experimental groups 
was observed upon correction and the pooled QC samples were found to be tightly 
clustered towards the centre of the scores plot. While complete discrimination was not 
achieved, a degree of separation of the IPF samples from the other HC and COPD 
(except sample 6) samples was observed. The COPD sample 6 appeared to be sitting 
within the IPF cluster while the three HC outliers were still identified prior to and 
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following QC corrections.  These were likely to have been caused by multiple sampling 
sites, inconsistencies in sample collection or mislabelled samples. 
 
 
 
 
Figure 2.1 Principal component analysis scores plots using the first two principal 
components showing all samples analysed. PCA plot (A) was generated before 
background correction and PCA plot (B) was generated after the corrections were 
applied. Black, blue, green and red squares represent pooled QC samples, IPF samples, 
healthy controls and COPD samples, respectively. 
 
 
 
A 
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To further separate the disease groups, a supervised approach using OPLS-DA 
modelling was applied. OPLS-DA was performed to evaluate the differences between 
the following groups: HC and COPD, HC and IPF, and between COPD and IPF. The 
OPLS-DA models presented in Figure 2.2 resulted in acceptable model characteristics 
and showed distinct sample grouping. The remaining samples (HC versus IPF, COPD 
versus IPF) were found to be well-separated along the predictive component axis (t[1]). 
The OPLS-DA prediction model was able to classify the samples into the respective 
COPD and IPF diseased groups. The scores plot for COPD versus IPF showed a similar 
trend to the OPLS-DA model for HC versus IPF and was presented in Figure 2.3 with 
two outliers. COPD sample 6 was the same outlier identified in the PCA and was 
positioned near the IPF cluster while the IPF sample 2 outlier fell outside the disease 
cluster. To improve the modelling, both the outliers were removed and the OPLS-DA 
scores plot was fitted again. Figure 2.3B showed an improved, well clustered OPLS-DA 
model which clearly separated the two diseases.  
 
S-plots were then derived from each of the OPLS-DA models and were used to identify 
features of interest unique to each group based on covariance and correlation between 
the ion features and causative factors (Ni et al., 2008; Worley and Powers, 2013). The 
ions in the S-plot furthest away from the origin were regarded as the most significant 
endogenous features within the study-specific group. The 10 most statistically 
significant features from each group within the S-plots were then selected and subjected 
to database matching. With this approach, only metabolite features with strong model 
contribution and high reliability were selected. A total of 60 features of interest were 
annotated using LIPID MAPS, Biomolecules, ChEBI, HMDB and Drug Bank databases 
with a specified mass error of 10 ppm. By comparing the accurate mass values, 
chemical formula and isotopic similarities, seven features were putatively identified, 
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and the results were listed in Table 2.1. The fold-change of the putative identities of 
interest between COPD and HC, IPF and HC, and COPD and IPF were also calculated 
and presented in Table 2.1. All other related statistics and database information were 
summarised in Supplementary Table 2.2. 
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Figure 2.2 Orthogonal Projection to Latent Structure-Discriminant Analysis (OPLS-DA) models between HC and COPD samples (A), and HC and IPF 
samples (B). The S-plots generated from the respective OPLS-DA scores plots were presented directly below. Blue, green and red squares represent 
IPF samples, healthy controls and COPD samples, respectively. 
A B 
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Figure 2.3 Orthogonal Projection to Latent Structure-Discriminant Analysis (OPLS-DA) models between COPD and IPF samples. The two observed 
outliers (COPD sample 6 and IPF sample 2) were removed and the OPLS-DA scores plot was fitted resulting in the model on the right. The S-plot 
generated from newly fitted OPLS-DA model was presented directly below. Red and blue squares represent COPD and IPF samples, respectively. 
A B 
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Table 2.1 The m/z values, putative identification and fold changes of features of interest 
derived using multivariate statistics and database matching. Additional filtering criteria 
including CV < 30%, mass accuracy < 10 ppm and VIP ≥ 1 were also applied. 
 
Database Feature m/z Putative Identification Fold Changes 
LipidMAPS 281.2491 Linoleic acid 
COPD→HC IPF→HC IPF→COPD 
1.73 2.13 1.23 
255.2331 Palmitoleic acid 2.88 2.69 0.93 
 
283.2647 Oleic acid 2.15 2.48 1.15 
 
468.3122 Arachidonoyl tyrosine 1.30 0.85 0.65 
 
447.3488 Dihydrotesterone 0.06 0.08 1.30 
Biomolecules 281.2491 Linoleic acid 1.73 2.13 1.23 
 
255.2331 Palmitoleic acid 2.79 2.86 1.03 
 
283.2647 Oleic acid 2.06 2.53 1.23 
 
585.2721 Bilirubin 1.33 0.70 0.53 
ChEBI 281.2491 Linoleic acid 1.73 2.13 1.23 
 
255.2331 Palmitoleic acid 2.79 2.86 1.03 
 
283.2647 Oleic acid 2.06 2.53 1.23 
 
447.3488 Dihydrotesterone 0.06 0.08 1.36 
 
585.2721 Bilirubin 1.33 0.70 0.53 
HMDB 281.2491 Linoleic acid 1.73 2.13 1.23 
 
255.2331 Palmitoleic acid 2.79 2.86 1.03 
 
283.2647 Oleic acid 2.06 2.53 1.23 
 
447.3488 Dihydrotesterone 0.06 0.08 1.36 
 
223.0970 LysoPC 0.41 1.02 2.46 
DrugBank 281.2491 Linoleic acid 1.73 2.13 1.23 
 
255.2331 Palmitoleic acid 2.79 2.86 1.03 
 
283.2647 Oleic acid 2.06 2.53 1.23 
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A total of 46 discriminative features were identified after the application of multivariate 
statistical analyses. Of these, four metabolic features with m/z 468.3122, m/z 496.3437, 
m/z 313.1556 and m/z 293.0996 were not identified due to unsuccessful library 
matching. Features m/z 281.2491, m/z 255.2331, m/z 283.2647 were putatively 
identified as linoleic acid, palmitoleic acid and oleic acid, respectively. Linoleic and 
oleic acids were shown to be consistently two-folds higher in COPD and IPF samples 
compared to the HC while palmitoleic acid was more than two-fold up-regulated in both 
disease cohorts. Two features were shown to be down-regulated; m/z 447.3488 was 
identified as dihydrotestosterone which was lower in abundance in COPD and IPF 
compared to HC while m/z 223.0970 was identified as a LysoPC and was approximately 
two-fold down-regulated in COPD compared to IPF and HC. Bilirubin and 
arachidonoyl tyrosine were assigned to feature m/z 585.2721 and m/z 468.3122 and 
showed approximately two-fold decreased in abundance for the IPF cohort compared to 
COPD and HC. Interestingly, all features with significant differences in abundance were 
either lipid mediators or constituents except for bilirubin. Of note, work published by 
Bulmer et al. (2013), Vogel et al. (2017) and Suh et al. (2018) described the potential 
association between bilirubin homeostasis and lipid pathophysiology in diseases such as 
Gilbert’s syndrome, atherosclerosis and cardiovascular diseases. Bilirubin is an inert 
anti-oxidant which enhances the peroxisome proliferator-activated receptor alpha 
(PPARα) signalling pathway involved in fatty acid beta-oxidation and is a major 
regulator of the energy metabolism (Stec et al., 2016). 
 
COPD and IPF are both chronic inflammatory disorders of the respiratory system which 
are characterized by excessive matrix degradation and tissue fibrosis. Clinical 
phenotypes of COPD and IPF are largely distinguished by airflow limitation, 
destruction of alveolar cells and pulmonary emphysema in COPD and parenchymal 
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scarring, alveolar wall thickening and restrictive lung function impairment in IPF. In 
this study, we have shown that both COPD and IPF were characterized by an increased 
presence of lipid constituents such as essential fatty acids sampled from circulating 
plasma. 
 
Results from this study identified an upregulation of the levels of linoleic acid, 
palmitoleic acid and oleic acid in COPD and IPF compared to HC. De Castro et al. 
(2006), Gangopadhyay et al. (2012) and Titz et al. (2016) reported that lipid mediators, 
in particular linoleic acid and oleic acid, were up-regulated in blood samples from 
COPD patients. The work of Balgoma et al. (2016) also supported the findings of this 
current study by showing an increase in linoleic acid-derived lipid mediators in COPD 
brochoalveolar lavage fluid (BALF) samples. Plasma linoleic, palmitoleic and oleic 
acids were also found to be elevated in patients suffering from interstitial lung disease 
(Steffen et al., 2018) and cystic fibrosis (Durieu et al., 2007). This increase in fatty 
acids suggested a tighter and more structured organisation of phospholipids within the 
plasma membrane resulting in lesser fluidity. Membrane fluidity in erythrocytes have 
been shown to decrease in COPD patients (Gangopadhyay et al., 2012), causing the 
lipid rafts to become more tightly packed and less mobile in the plane of membranes 
leading to their dysfunction.  
 
Linoleic acid can enzymatically produce epoxides via CYP activity which are further 
converted to leukotoxin and isoleukotoxin diols (Balgoma et al., 2016). These diols 
have been shown to exert cytotoxicity as they decrease net ion flux in alveolar epithelial 
monolayers and increase intercellular junction permeability (Shen and Hammock, 2012). 
These are known to contribute to chronic bronchitis (Balgoma et al., 2016). Chronic 
bronchitis is a prevalent clinical manifestation among COPD patients, especially within 
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the “smokers” cohort of the disease. The role of oleic acid as an inhibitor of the Na/K-
ATPase activity have been demonstrated in rabbit lung model (Vadasz et al., 2005), 
increasing endothelial permeability. Oleic acid has also been shown to induce acute 
respiratory distress syndrome (ARDS) in experimental models and lung injury were 
associated with elevated levels of lipid mediators (Akella et al., 2014). Gonçalves-de-
Albuquerque et al. (2012) suggested the participation of the Na/K-ATPase as the main 
target of oleic acid in the mechanism of ERK activation pathway in lung inflammation.  
 
Although there are limited reports of palmitoleic acid in previous COPD or IPF studies, 
this FA may be an important biomarker of the disease as it is one of the most abundant 
FAs in serum, liver and adipose tissues (Frigolet, and Gutiérrez-Aguilar., 2017). This 
study found an approximate three-fold increase in plasma palmitoleic acid in patients 
suffering from COPD and IPF compared to HC. Palmitoleic acid have also been 
associated with some cancer types. Prostate and breast cancer risk and incidence were 
increased with augmented palmitoleic acid concentration in blood (Chavarro et al., 
2013; Pouchieu et al., 2014). The correlation of palmitoleic acid in serum and plasma to 
variation within the SCD1 gene were shown to be associated with cancer mortality 
(Byberg et al., (2014); Manni et al., 2017). Mechanistically, SCD1 promotes cell 
survival through palmitoleic acid production and is hypothesised to be the underlying 
cause of cell proliferation and survival in cancer progression (Frigolet and Gutiérrez-
Aguilar., 2017). Using a bleomycin-induced fibrosis in a mice lung model, Sunaga et al. 
(2013) reported an increase in palmitoleic acid when elongation of the long chain fatty 
acids (Elovl6) rate-limiting enzyme is deficient. Elovl6 deficiency leads to the apoptotic 
effect of alveolar type 2 cells and caspase 3 activation in the lung, which result in the 
initiation and progression of fibrosis (Sunaga et al., 2013).  
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Interestingly, this study also showed that dihydrotestosterone was severely down-
regulated in patients with COPD and IPF by approximately 90%. Dihydrotestosterone 
and its 5α-reductase precursor, testosterone, are the predominant androgens in mammals. 
Testosterone levels have been shown to be reduced in patients with asthma (Canguven 
and Albayrak, 2011; Montano et al., 2014), cystic fibrosis (Leifke et al., 2003; 
Blackman and Tangpricha, 2016), hypoxic pulmonary fibrosis (Semple et al., 1984) and 
COPD (Svartberg et al., 2007; Laghi et al., 2009; Mousavi et al., 2012; Corbo et al., 
2014). The relaxant effect of testosterone may be important for understanding the 
pathophysiology of these lung diseases as it has been shown to affect the responsiveness 
of tracheal smooth muscles as well as the integrity of epithelium (Kouloumenta et al., 
2009).  
 
Factors that decrease testosterone levels in patients with COPD includes smoking, 
systemic inflammation and ageing (Laghi et al., 2009; Daabis et al., 2016). Testosterone 
deficiency along with the aforementioned risk factors can exacerbate COPD symptoms 
through a direct impact on respiratory muscles, diminishing overall strength and 
breathing capacity. An in vivo study conducted by Montano et al. (2014) showed that 
low circulatory testosterone and its metabolite, dihydrotestosterone was positively 
associated with reduced lung function in guinea pigs with allergic asthma. Furthermore, 
these androgens have been shown to induce relaxation of airway smooth muscle and 
mediated via decreased Ca2+ influx through the L-type Ca2+ channels in tracheal 
myocytes. Testosterone supplementation have also improved skeletal muscle strength 
and exercise capacity in COPD patients by acting as bronchoactive compounds to 
prevent airway spasm (Laghi et al., 2009; Baillargeon et al., 2018).  
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Like testosterone, LysoPC may also be associated with Ca2+ sensitisation in tracheal 
myocytes. LysoPCs are involved in eosinophils infiltration and bronchoconstriction 
(Nishiyama et al., 2014), and studies by Kume et al. (2001), Nobata et al. (2005) and 
Bansal et al. (2016) linked LysoPC to the allergic cascade in airway diseases like 
asthma. These studies showed LysoPC-induced expression of various adhesion 
molecules on the vascular endothelium and increases permeability, which led to 
inflammation in the lungs. However, the LysoPC levels reported were higher in the 
asthmatic cohort as opposed to the down-regulation observed in our study. Yoder et al. 
(2014) also supported the increased level of LysoPC by demonstrating the elevation in 
BALF samples of asthmatic patients. A lung cancer biomarker study by Dong et al. 
(2011) reported a decrease of LysoPCs in plasma samples. LysoPCs can be converted to 
phosphatidylcholines by LysoPC acyltransferase in the lung surfactant, where lung 
surface tension is maintained to preserve essential respiratory functions. Although there 
were no changes in LysoPC levels between IPF and HC, the two-fold increase between 
IPF and COPD was indicative of LysoPC’s emerging role in IPF pathogenesis. 
Rindlisbacher et al. (2018) consistently found elevated amounts of LysoPC in serum 
samples from IPF patients compared to healthy individuals. LysoPC is also a precursor 
of lysophosphatidic acid (LPA), a bioactive glycerophospholipid. LPA has been shown 
to induce fibrosis in the lungs and other organs including kidney and liver via epithelial 
cell death, vascular leakage and fibroblastic proliferation (Tager et al., 2008; Kaffe et 
al., 2016; Alsafadi et al., 2017; Sakai et al., 2017).  
 
There appeared to be no difference between the levels of bilirubin and arachidonoyl 
tyrosine in COPD and HC samples. However, the levels of both compounds were found 
to be down-regulated in the IPF cohort compared to both HC and COPD. In the haem 
degradation pathway, haem oxygenase converts haem to biliverdin which is then 
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converted to bilirubin using biliverdin reductase before being excreted (Ye et al., 2008; 
Zhao et al., 2017). Haem oxygenase and bilirubin are considered to be oxidative stress 
responsive molecules involved in the pathogenesis of lung diseases such as 
hypersensitivity pneumonitis, sarcoidosis, lung cancer, COPD and IPF (Ye et al., 2008; 
Horsfall et al., 2011; Curjuric et al., 2014; Brown et al., 2017; Zhao et al., 2017). Their 
role in the pathogenesis of IPF may be explained in two ways: the downregulation may 
either serve as an adaptive mechanism to protect the tissue against harmful effects of 
haem degradation products (Ye et al., 2008), or it may indicate a loss of protection 
against oxidative stress (Curjuric et al., 2014). The beneficial effects of serum bilirubin 
on respiratory outcomes have been reported in several lung studies. High serum 
bilirubin was associated with lower cancer mortality, including that of lung cancer 
(Brown et al., 2017). Horsfall et al. (2011) demonstrated that higher levels of bilirubin 
were associated with a lower risk of respiratory diseases such as lung cancer and COPD 
and caused mortality among patients with normal-range bilirubin levels in primary care 
practices in the United Kingdom. Zhao et al. (2017) showed that an up-regulation of 
haem degradation pathway that supported the hypothesis of an oxidant-antioxidant 
imbalance in the pathogenesis of IPF.  
 
We have also identified an endogenous lipid, arachidonoyl tyrosine, responsible for N-
arachidonoyl dopamine (NADA) biosynthesis. NADA plays an important role in pain 
and inflammation and its synthesis primarily occurs through an enzyme-mediated 
conjugation of arachidonic acid with dopamine (Grabiec and Dehghani, 2017). A study 
by Wilhelmsen et al. (2014) demonstrated that a reduction in NADA led to 
inflammatory responses in human lung microvascular endothelial cells. The study also 
reported the ability of inflammatory agonists such as bacterial lipopeptides and tumour 
necrotic factor-alpha (TNF-α) dampened the activation of the primary endothelial cells. 
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Although NADA was not detected in our study, the down-regulation of its precursor 
arachidonoyl tyrosine may potentially contribute to the inflammatory response in IPF. 
 
In this study, we identified a number of unique lipid mediators including linoleic, 
palmitoleic and oleic acids that suggest dysregulated metabolic pathways associated 
with lung inflammation and progression of fibrosis (Sunaga et al., 2013; Daabis et al., 
2016). The analysis also detected arachidonoyl tyrosine, bilirubin, dihydrotestosterone 
and lysoPC, metabolites that play key roles in regulating the lung energy metabolism 
(Brown et al., 2017; Zhao et al., 2017). While the OPLS-DA approach provided robust 
classification models, a separate validation study is required to confirm these findings. 
Future correlation studies incorporating patient demographics and metadata 
(Supplementary Table 2.1) will also strengthen the multivariate statistical models as 
well as aid in disease stratification. Targeted analysis and data-independent acquisition 
strategies reported by Gethings et al. (2017) and Moseley et al. (2018) can also be used 
to provide qualitative and quantitative measurements to establish reference levels of 
disease. 
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2.5 Conclusion 
 
COPD and IPF are complex lung disorders that are poorly defined to their 
heterogeneous phenotypes and poses considerable challenges in the development of 
accurate diagnostics. Here, we showed that untargeted profiling of plasma by UHPLC-
QTOF-MS followed by the application of multivariate statistics provided an efficient 
and robust metabolomics pipeline for the investigation of plasma from different 
pulmonary conditions. The multivariate statistical models generated were able to 
discriminate diseased patients from healthy controls. In addition, this study also showed 
potential dysregulation of the cellular energy metabolism in COPD and IPF based on 
the identification of metabolites that are associated with increased inflammation and 
oxidative stress in the lung.  
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Supplementary Table 2.1 Patient demographics and clinical characteristics including sex, age, history of smoking as well as c-reactive protein (CRP), 
soluble tumour necrosis factor receptor-1 (sTNFR1), forced expiratory volume in 1 sec (FEV1) and forced vital capacity (FVC) levels. 
 
 Sex Age Smoking CRP (mg/L) sTNFR1 (pg/mL) FEV1 (L) FEV1 (%) FVC FVC %  FEV1/FVC ratio 
Healthy subjects 
 
          
1 Male 63 non-smoker 0.06 588 n/a n/a n/a n/a n/a 
2 Female 57 non-smoker 0.06 513 n/a n/a n/a n/a n/a 
3 Male 63 non-smoker 0.89 767 n/a n/a n/a n/a n/a 
4 Male 60 non-smoker 4.46 480 n/a n/a n/a n/a n/a 
5 Female 54 non-smoker 6.14 413 n/a n/a n/a n/a n/a 
6 Male 90 non-smoker 0.65 642 n/a n/a n/a n/a n/a 
7 Female 77 non-smoker 0.80 652 n/a n/a n/a n/a n/a 
8 Male 56 non-smoker 5.96 557 n/a n/a n/a n/a n/a 
9 Male 61 non-smoker 0.84 715 n/a n/a n/a n/a n/a 
10 Female 77 non-smoker 0.40 502 n/a n/a n/a n/a n/a 
11 Male 78 ex-smoker 0.39 477 n/a n/a n/a n/a n/a 
12 Male 84 ex-smoker 0.58 410 n/a n/a n/a n/a n/a 
13 Male 75 never smoked 1.01 621 n/a n/a n/a n/a n/a 
14 Male 78 ex-smoker 0.69 374 n/a n/a n/a n/a n/a 
15 Female 74 never smoked 1.00 517 n/a n/a n/a n/a n/a 
16 Male 76 ex-smoker 2.34 737 n/a n/a n/a n/a n/a 
17 Female 76 ex-smoker 0.41 529 n/a n/a n/a n/a n/a 
18 Male 83 never smoked 7.12 622 n/a n/a n/a n/a n/a 
19 Female 80 never smoked 0.85 524 n/a n/a n/a n/a n/a 
20 Female 77 ex-smoker 2.02 443 n/a n/a n/a n/a n/a 
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COPD patients 
 
          
1 Male 64 ex-smoker 10.73 297 2.07 55% 3.80 75% 0.54 
2 Male 83 ex-smoker 6.95 901 0.57 25% n/a n/a n/a 
3 Male 69 ex-smoker 11.23 503 1.01 34% 3.26 81% 0.31 
4 Male 84 ex-smoker 45.21 990 1.19 63% 2.49 89% 0.48 
5 Female 77 ex-smoker 5.80 468 0.77 38% 2.68 99% 0.29 
6 Female 60 ex-smoker 5.24 630 0.99 41% 2.97 95% 0.33 
7 Male 70 ex-smoker 2.52 351 0.60 21% 2.79 71% 0.22 
8 Female 77 ex-smoker 2.84 563 0.63 42% 1.28 63% 0.49 
9 Male 75 ex-smoker 2.84 365 1.13 47% 2.66 79% 0.42 
10 Male 76 ex-smoker 8.67 518 0.83 30% 2.28 60% 0.36 
11 Male 82 ex-smoker 6.26 599 0.99 34% 2.27 56% 0.44 
12 Male 82 ex-smoker 3.02 650 1.29 54% 2.90 84% 0.44 
13 Male 79 ex-smoker 26.15 1432 0.73 31% n/a n/a n/a 
14 Male 69 ex-smoker 26.61 449 0.86 25% n/a n/a n/a 
15 Male 65 ex-smoker 2.81 558 1.45 42% 4.12 89% 0.35 
16 Male 69 ex-smoker 38.10 854 1.43 45% 2.88 66% 0.50 
17 Female 89 ex-smoker 177.83 1321 0.67 41% 1.88 85% 0.36 
18 Female 79 ex-smoker 2.64 760 0.81 49% 1.55 69% 0.52 
19 Female 66 ex-smoker 11.69 504 0.64 26% 1.92 59% 0.33 
20 Male 81 ex-smoker 12.64 662 1.75 74% 3.56 106% 0.49 
           
IPF patients 
 
          
1 Male 64 ex-smoker n/a n/a n/a n/a 2.79 68 n/a 
2 Male 73 ex-smoker n/a n/a n/a n/a 1.38 59 n/a 
3 Male 75 ex-smoker n/a n/a n/a n/a 2.84 67 n/a 
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4 Male 69 ex-smoker n/a n/a n/a n/a 2.31 64 n/a 
5 Male 79 only teen n/a n/a n/a n/a 2.65 103 n/a 
6 Male 71 ex-smoker n/a n/a n/a n/a 3.7 85.1 n/a 
7 Female 71 ex-smoker n/a n/a n/a n/a 2.53 95.5 n/a 
8 Male 67 3 pack/years n/a n/a n/a n/a 3.43 79 n/a 
9 Male 74 ex-smoker n/a n/a n/a n/a 2.18 60 n/a 
10 Male 63 ex-smoker n/a n/a n/a n/a 1.56 48 n/a 
11 Male 73 ex-smoker n/a n/a n/a n/a 4.09 83 n/a 
12 Male 60 never smoked n/a n/a n/a n/a 3.63 69 n/a 
13 Male 63 ex-smoker n/a n/a n/a n/a 2.7 69 n/a 
14 Male 66 ex-smoker n/a n/a n/a n/a 1.72 38 n/a 
15 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
16 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
17 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
18 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
19 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
20 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
21 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
22 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
23 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
24 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
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Supplementary Table 2.2 The m/z values, chemical formulas, mass error, percentage isotopic similarities, ANOVA p-values as well as the mean 
abundances, relative standard deviations and fold changes of metabolite features annotated using LIPID MAPS, Biomolecules, ChEBI, HMDB and 
Drug Bank databases. 
 
Database Feature 
m/z 
Adduct Chemical 
Formula 
Mass 
error 
ppm 
Isotope 
similarity 
% 
ANOVA 
p-value 
HC COPD IPF 
Mean %RSD Mean %RSD FoldChange 
(HC) 
Mean %RSD FoldChange 
(HC) 
FoldChange 
(COPD) 
LipidMAPS 281.2491 M+H C18H32O2 5.54 97.27 1.49E-02 4536.05 56.00 8064.56 53.36 1.78 9360.56 71.77 2.06 1.16 
 255.2331 M+H  C16H30O2 5.06 98.13 3.71E-03 1609.23 78.95 4631.58 80.14 2.88 4321.82 109.58 2.69 0.93 
 496.3438 M+H  C24H50NO7P 8.08 97.56 1.62E-01 39778.32 51.50 44409.52 36.73 1.12 43429.30 43.27 1.09 0.98 
 520.3439 M+H  C26H50NO7P 7.88 95.52 5.87E-02 80004.33 51.42 93608.97 48.55 1.17 101194.74 32.95 1.26 1.08 
 283.2647 M+H C18H34O2 5.36 98.25 7.68E-03 7578.42 69.48 16301.89 63.55 2.15 18783.78 86.80 2.48 1.15 
 522.3599 M+H C26H52NO7P 8.61 97.12 4.75E-02 67351.83 49.75 87303.54 40.89 1.30 82801.42 41.51 1.23 0.95 
 468.3122 M+H C29H41NO4 2.87 94.11 3.14E-01 15422.84 56.00 20010.25 77.11 1.30 13094.73 48.42 0.85 0.65 
 331.0558 M+Na C18H12O5 -6.21 87.60 1.71E-06 4708.33 230.43 100.70 96.11 0.02 1171.62 458.27 0.25 11.63 
 293.0996 M+H C15H16O6 -8.12 96.49 4.32E-09 209813.07 229.66 2847.12 440.84 0.01 52210.26 487.94 0.25 18.34 
 447.3488 M+H C28H46O4 4.26 90.74 8.20E-03 2921.88 249.00 172.58 56.53 0.06 225.02 80.78 0.08 1.30 
 585.2721 M+H C32H40O10 4.61 94.42 1.40E-01 11453.01 104.67 14930.72 66.02 1.30 7569.45 73.91 0.66 0.51 
 496.3437 M+Na C29H47NO4 8.28 98.60 1.80E-02 249023.62 50.68 270223.09 37.53 1.09 263898.71 33.44 1.06 0.98 
Biomolecules 281.2491 M+H C18H32O2 5.54 97.27 1.49E-02 4536.05 56.00 7837.51 54.66 1.73 9647.57 70.19 2.13 1.23 
 255.2331 M+H   C16H30O2 5.06 98.13 3.71E-03 1609.23 78.95 4490.77 83.51 2.79 4606.20 109.22 2.86 1.03 
 283.2647 M+H C18H34O2 5.36 98.25 7.68E-03 7578.42 69.48 15582.64 64.67 2.06 19196.91 86.39 2.53 1.23 
 468.3122 M+H C29H41NO4 2.87 94.11 3.14E-01 15422.84 56.00 20004.03 79.14 1.30 14213.15 44.43 0.92 0.71 
 429.2415 M+H C25H28N6O 4.12 96.62 4.32E-07 17499.11 282.30 18062.47 225.41 1.03 26.04 86.34 0.00 0.00 
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 313.1556 M+H C18H20N2O3 3.14 96.44 n/a 144.47 38.64 869.71 329.98 6.02 20131.64 50.55 139.34 23.15 
 315.0818 M+H C16H14N2O3S 6.44 89.81 8.65E-08 26567.24 213.41 2046.02 259.84 0.08 9644.79 413.46 0.36 4.71 
 331.0558 M+H C10H16N2O8 6.70 93.02 1.71E-06 4708.33 230.43 99.76 99.44 0.02 1390.65 422.95 0.30 13.94 
 293.0996 M+K C11H18N4O3 -5.73 93.13 4.32E-09 209813.07 229.66 2982.96 431.17 0.01 62615.82 445.68 0.30 20.99 
 447.3488 M+K C28H46O4 4.26 90.74 8.20E-03 2921.88 249.00 169.17 58.41 0.06 229.82 82.81 0.08 1.36 
 585.2721 M+H C33H36N4O6 2.32 95.97 1.40E-01 11453.01 104.67 15262.54 65.47 1.33 8041.90 74.82 0.70 0.53 
 223.0970 M+H C12H14O4 2.31 98.15 1.80E-02 4507.94 80.66 1863.27 106.55 0.41 4590.72 93.35 1.02 2.46 
 239.0920 M+H C12H14O5 2.58 97.78 4.63E-02 3225.57 66.91 1005.22 125.71 0.31 2495.10 75.73 0.77 2.48 
 496.3437 M+H C29H47NO4 8.28 98.60 3.18E-02 249023.62 50.68 269158.70 38.61 1.08 277718.21 31.27 1.12 1.03 
ChEBI 281.2491 M+Na C18H32O2 5.54 97.27 1.49E-02 4536.05 56.00 7837.51 54.66 1.73 9647.57 70.19 2.13 1.23 
 255.2331 M+H C16H30O2 5.06 98.13 3.71E-03 1609.23 78.95 4490.77 83.51 2.79 4606.20 109.22 2.86 1.03 
 496.3438 M+H C24H50NO7P 8.08 97.56 1.62E-01 39778.32 51.50 44017.40 37.79 1.11 46390.68 39.97 1.17 1.05 
 283.2647 M+H C18H34O2 5.36 98.25 7.68E-03 7578.42 69.48 15582.64 64.67 2.06 19196.91 86.39 2.53 1.23 
 522.3599 M+H C26H52NO7P 8.61 97.12 4.75E-02 67351.83 49.75 87148.02 42.02 1.29 87175.00 39.70 1.29 1.00 
 468.3122 M+H C29H41NO4 2.87 94.11 3.14E-01 15422.84 56.00 20004.03 79.14 1.30 14213.15 44.43 0.92 0.71 
 429.2415 M+H C25H28N6O 4.12 96.62 4.32E-07 17499.11 282.30 18062.47 225.41 1.03 26.04 86.34 0.00 0.00 
 308.0520 M+H C9H13Cl2N6O2 -9.78 54.88 8.99E-08 5.67 253.33 6612.98 163.54 1166.63 862.41 307.46 152.14 0.13 
 313.1556 M+H C18H20N2O3 3.14 96.44 n/a 144.47 38.64 869.71 329.98 6.02 20131.64 50.55 139.34 23.15 
 315.0818 M+H C16H14N2O3S 6.44 89.81 8.65E-08 26567.24 213.41 2046.02 259.84 0.08 9644.79 413.46 0.36 4.71 
 371.1036 M+H C19H18N2O4S -6.42 77.03 1.97E-02 26571.60 70.41 45650.74 52.16 1.72 39475.60 69.44 1.49 0.86 
 331.0558 M+H C10H16N2O8 6.70 93.02 1.71E-06 4708.33 230.43 99.76 99.44 0.02 1390.65 422.95 0.30 13.94 
 293.0996 M+H C11H18N4O3 -5.73 93.13 9.00E-03 209813.07 229.66 2982.96 431.17 0.01 62615.82 445.68 0.30 20.99 
 447.3488 M+K C28H46O4 4.26 90.74 4.32E-09 2921.88 249.00 169.17 58.41 0.06 229.82 82.81 0.08 1.36 
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 346.0119 M+K C9H13Cl2N6O2 3.50 56.12 8.20E-03 23944.57 204.03 1718.13 300.36 0.07 4754.14 425.09 0.20 2.77 
 585.2721 M+H C33H36N4O6 2.32 95.97 1.40E-01 11453.01 104.67 15262.54 65.47 1.33 8041.90 74.82 0.70 0.53 
 223.0970 M+K C12H14O4 2.31 98.15 2.08E-08 4507.94 80.66 1863.27 106.55 0.41 4590.72 93.35 1.02 2.46 
 239.0920 M+H C12H14O5 2.58 97.78 1.14E-04 3225.57 66.91 1005.22 125.71 0.31 2495.10 75.73 0.77 2.48 
 496.3437 M+H C29H47NO4 8.28 98.60 1.80E-02 249023.62 50.68 269158.70 38.61 1.08 277718.21 31.27 1.12 1.03 
HMDB 281.2491 M+H C18H32O2 5.54 97.27 1.49E-02 4536.05 56.00 7837.51 54.66 1.73 9647.57 70.19 2.13 1.23 
 255.2331 M+Na C16H30O2 5.06 98.13 3.71E-03 1609.23 78.95 4490.77 83.51 2.79 4606.20 109.22 2.86 1.03 
 496.3438 M+H C24H50NO7P 8.08 97.56 1.62E-01 39778.32 51.50 44017.40 37.79 1.11 46390.68 39.97 1.17 1.05 
 520.3439 M+H C26H50NO7P 7.88 95.52 5.87E-02 80004.33 51.42 94824.45 48.80 1.19 106630.98 31.66 1.33 1.12 
 283.2647 M+H C18H34O2 5.36 98.25 7.68E-03 7578.42 69.48 15582.64 64.67 2.06 19196.91 86.39 2.53 1.23 
 522.3599 M+H C26H52NO7P 8.61 97.12 4.75E-02 67351.83 49.75 87148.02 42.02 1.29 87175.00 39.70 1.29 1.00 
 468.3122 M+H C29H41NO4 2.87 94.11 3.14E-01 15422.84 56.00 20004.03 79.14 1.30 14213.15 44.43 0.92 0.71 
 429.2415 M+H C25H28N6O 4.12 96.62 4.32E-07 17499.11 282.30 18062.47 225.41 1.03 26.04 86.34 0.00 0.00 
 313.1556 M+H C18H20N2O3 3.14 96.44 n/a 144.47 38.64 869.71 329.98 6.02 20131.64 50.55 139.34 23.15 
 315.0818 M+H  C16H14N2O3S 6.44 89.81 8.65E-08 26567.24 213.41 2046.02 259.84 0.08 9644.79 413.46 0.36 4.71 
 604.2959 M+H C29H41N5O9 -2.95 78.11 1.71E-06 4.53 84.40 629.06 438.73 138.75 5037.93 86.00 1111.20 8.01 
 331.0558 M+H C10H16N2O8 6.70 93.02 4.32E-09 4708.33 230.43 99.76 99.44 0.02 1390.65 422.95 0.30 13.94 
 293.0996 M+H C28H46O4 4.26 90.74 8.20E-03 209813.07 229.66 2982.96 431.17 0.01 62615.82 445.68 0.30 20.99 
 447.3488 M+H C33H36N4O6 2.32 95.97 1.40E-01 2921.88 249.00 169.17 58.41 0.06 229.82 82.81 0.08 1.36 
 585.2721 M+K C12H14O4 2.31 98.15 4.63E-02 11453.01 104.67 15262.54 65.47 1.33 8041.90 74.82 0.70 0.53 
 223.0970 M+H C24H48NO7P 6.18 95.04 1.09E-01 4507.94 80.66 1863.27 106.55 0.41 4590.72 93.35 1.02 2.46 
 239.0920 M+H C12H14O5 2.58 97.78 4.63E-02 3225.57 66.91 1005.22 125.71 0.31 2495.10 75.73 0.77 2.48 
 496.3437 M+H C29H47NO4 8.28 98.60 3.18E-02 249023.62 50.68 269158.70 38.61 1.08 277718.21 31.27 1.12 1.03 
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DrugBank 281.2491 M+H C18H32O2 5.54 97.27 1.49E-02 4536.05 56.00 7837.51 54.66 1.73 9647.57 70.19 2.13 1.23 
 255.2331 M+H C16H30O2 5.06 98.13 3.71E-03 1609.23 78.95 4490.77 83.51 2.79 4606.20 109.22 2.86 1.03 
 283.2647 M+Na C18H34O2 5.36 98.25 7.68E-03 7578.42 69.48 15582.64 64.67 2.06 19196.91 86.39 2.53 1.23 
 468.3122 M+H C29H41NO4 2.87 94.11 3.14E-01 15422.84 56.00 20004.03 79.14 1.30 14213.15 44.43 0.92 0.71 
 429.2415 M+H C25H28N6O 4.12 96.62 4.32E-07 17499.11 282.30 18062.47 225.41 1.03 26.04 86.34 0.00 0.00 
 315.0818 M+H C16H14N2O3S 6.44 89.81 8.65E-08 26567.24 213.41 2046.02 259.84 0.08 9644.79 413.46 0.36 4.71 
 371.1036 M+H C20H16N2O4 9.77 73.89 1.97E-02 26571.60 70.41 45650.74 52.16 1.72 39475.60 69.44 1.49 0.86 
 293.0996 M+H C10H16N2O8 5.65 92.55 4.32E-09 209813.07 229.66 2982.96 431.17 0.01 62615.82 445.68 0.30 20.99 
 239.0920 M+H C6H12N3O4P 7.45 92.53 3.18E-02 3225.57 66.91 1005.22 125.71 0.31 2495.10 75.73 0.77 2.48 
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SONAR enhances the specificity of unbiased lipid plasma profiling of idiopathic 
pulmonary fibrosis using UPLC-QTOF-MS 
 
Adapted from Nambiar, S.; Bong, S. H..; King, A.; Moodley, Y.; and Trengove, R. D. 
(2018) “SONAR enhances the specificity of unbiased lipid plasma profiling of 
idiopathic pulmonary fibrosis using UPLC-QTOF-MS” Ready for submission to 
Analytica Chimica Acta 
 
3.1 Abstract 
 
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial disease characterized by 
fibrosis and progressive loss of lung function. The pathophysiological pathways 
involved in IPF are not well understood. IPF is believed to be caused by repetitive 
alveolar epithelial cell injury and dysregulated repair mechanisms leading to 
uncontrolled proliferation of lung fibroblasts and excessive deposition of extracellular 
matrix in the interstitial space. In this study, we used ultra-performance liquid 
chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS) to 
characterize lipid changes in plasma derived from patients with stable and progressive 
IPF. We further applied a data independent acquisition (DIA) technique to improve the 
specificity by generating class-specific fragment ions through the use of a scanning 
quadrupole positioned prior to orthogonal acceleration TOF mass analyser. This DIA 
approach, known as SONAR, allowed specific precursor (MS1) and associated product 
ions (MS2) to be aligned on the basis of the quadrupole m/z position during the scan. 
Supervised partial least-squares discriminant analysis (OPLS-DA) modelling showed 
discrimination between the stable and progressive subjects. The study revealed up-
regulation of triglycerides while phosphatidylcholines were down-regulated in the 
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progressors versus stable group. These lipids were then identified by matching 
experimental fragment ions with in silico product ion spectra from LIPID MAPS with a 
mass tolerance of 10 ppm. The result of this study suggested a role for lipid metabolism 
dysregulation and mitochondrial-beta oxidation in progressive IPF samples and 
highlighted a number of promising candidates for biomarker development. 
 
Keywords: lipids, plasma, IPF, DIA, SONAR 
 
3.2 Introduction 
 
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized 
by alveolar epithelial cell damage, proliferation of activated fibroblasts and extracellular 
matrix accumulation that leads to irreversible distortion of the lung architecture (Kang 
et al., 2016). Previous studies suggested that IPF is related to abnormalities in a number 
of biological processes including glycolysis (Kang et al., 2016), fatty acid oxidation 
(Hamanaka et al., 2018) and vascular remodelling (Zhao et al., 2017). While genetic 
and molecular mechanisms associated with the development of fibrosis have been 
reported by Gangwar et al. (2017) and Zhao et al. (2017), the underlying disease 
pathophysiology remains unclear.  
 
Advances in analytical technologies have enabled the analysis of complex biological 
matrices by liquid chromatography-mass spectrometry (LC-MS). The ability to 
determine specific biomolecules and their relative abundance has been key to the 
understanding of biochemical change. Lipidomics, like metabolomics, is a developing 
field of systems biology research that studies lipids as key intermediates of cellular 
mechanisms and their roles in diseases such as asthma (Berry et al., 2017) and chronic 
   Chapter 3 
 
80 
 
obstructive pulmonary disorder (COPD; Telenga et al., 2014). Lipidomic studies of 
complex biological matrices (plasma and tissue extracts) are routinely performed using 
targeted tandem mass spectrometry (MS/MS) or data dependent acquisition (DDA) 
methods for their high sensitivity and selectivity (Dautel et al., 2017; Kyle et al., 2018). 
The advent of high-resolution MS and data-independent acquisition (DIA) modes can 
now provide broad coverage for both MS and MS/MS data simultaneously in a single 
analytical run (Gethings et al., 2017).  
 
A key challenge in the analysis of complex lipid extracts from crude plasma samples is 
the co-elution of isomeric lipid species that can lead to false identification and 
quantitative inaccuracies (Cajka and Fiehn, 2014; Kyle et al., 2016). Here, we apply 
SONAR, a rapidly scanning DIA method in tandem with a UPLC-TOF-MS acquisition 
to provide additional MS/MS information. SONAR utilizes a narrow quadrupole scan 
window to provide cleaner spectra (Gethings et al., 2017), increase MS/MS spectral 
quality and consequently, improve compound database matching (Moseley et al., 2018). 
The qualitative and quantitative performance of SONAR compared to conventional 
quadrupole time-of-flight (QTOF)-MS method were assessed using plasma samples 
from stable and progressive IPF patients. Healthy controls were not included in this 
study as the principal aim of the study was to investigate plasma lipid differences 
between diseased groups. 
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3.3 Materials and Methods 
 
3.3.1 Chemicals and Reagents  
SPLASH LipidoMix standard (deuterium-labelled standard, SKU 330707), normalised 
against human plasma lipid levels, was purchased from Avanti Polar Lipids (Alabaster, 
USA). UPLC–MS grade water (H2O), acetonitrile (ACN) and isopropanol (IPA) were 
purchased from Thermo Fisher Scientific (Victoria, Australia). Formic acid and 
ammonium formate were sourced from Sigma-Aldrich (New South Wales, Australia) 
and the leucine enkaphalin standard for lock-mass acquisition was supplied by Waters 
(Wilmslow, United Kingdom). 
 
3.3.2 Biological samples 
 
A total of 60 plasma samples (30 stable and 30 progressors) were obtained from the 
Australian IPF registry and stored in -80 °C until further analysis. Sample handling and 
material transfer was approved by the Royal Perth Hospital Human Research Ethics 
Committee (Reference number: REG 15-204) and the experimental protocol used for 
this work was approved by the Murdoch University Human Research Ethics Committee 
(Approval number: 2017/254). 
 
3.3.3 Sample preparation 
 
The SPLASH LipidoMix standard was initially diluted 1:50 with IPA. Plasma samples 
were thawed on ice and immediately transferred to 96-well plates. 20 µL of samples 
were pipetted into each well followed by the addition of 30 µL of H2O. The extraction 
of lipids was carried out by adding 200 µL of IPA (consisting of the diluted SPLASH 
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LipidoMix) into each well. The plates were immediately heat-sealed using Eppendorf® 
heat sealing foil and mixed briefly before incubation for 2 hrs at 4 °C. Sample plates 
were removed and centrifuged at 4,500 x g for 10 mins at 4 °C. 100 µL of the 
supernatant were then transferred into two 96-well plates corresponding to positive and 
negative modes of acquisition. Pooled samples were also generated by aliquoting 20 µL 
of every sample into a 2-mL centrifuge tube and placed on ice. 20 µL of pooled QC was 
pipetted into every 12th well as the study reference or quality control (QC) checks. The 
extractions for study reference or QC samples were performed in the same way as the 
test samples. 
 
3.3.4 UPLC configuration 
 
UPLC separation was performed using an ACQUITY I-class system (Waters 
Corporation, Milford, MA, U. S. A) equipped with a Waters CSH C18 column (2.1 x 
100 mm, 1.8 µm). Mobile phase A consisted of ACN/H2O (60:40, v/v) containing 10 
mM ammonium formate with 0.1 % formic acid, while mobile phase B was IPA/ACN 
(90:10, v/v) with 0.1 % formic acid. Chromatographic separation was achieved with a 
gradient of 40 to 99 % mobile phase B over 18 mins. Solvent flow rate and column 
temperature was maintained at 0.4 mL/min and 55 °C, respectively.  The lock-mass 
compound, leucine enkaphlin (200 pg/μL) was prepared in ACN/H2O (50:50, v/v), and 
was delivered at 10 µL/min to the reference sprayer source of the mass spectrometer. 
 
3.3.5 Mass spectrometry acquisition 
 
MS-based lipid analysis was performed using a Xevo G2-XS QTOF mass spectrometer 
(Waters Corporation, Wilmslow, United Kingdom) in both positive and negative 
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electrospray ionisation (ESI) modes. The source temperature was set to 120 °C and the 
capillary voltage set to 2.0 kV and 1.0 kV for positive and negative mode respectively. 
The time-of-flight (TOF) mass analyser of the mass spectrometer was calibrated using a 
sodium formate mixture for m/z 50 to 1200. TOF-MS data were collected for the time-
of-flight-mass spectrometry (TOF-MS) method as well as SONAR DIA. During 
SONAR acquisition the quadrupole was rapidly scanned between m/z 350 to 950 and 
m/z 150 to 750 for positive and negative modes, respectively, using a quadrupole 
transmission window of 10 Da. For each quadrupole transmission window, the 
orthogonal-TOF mass spectra were recorded as the quadrupole scans into 200 discrete 
bins. Two data functions (modes) were acquired in an alternating fashion, differing only 
in the collision energy applied to the gas cell. In the low-energy function mode, data 
were collected with a constant gas cell collision energy of 6 eV. In the high-energy 
function mode, the gas cell collision energy was ramped from 20 to 40 eV. As such, the 
resulting data contained both lipid precursor ions as well as associated fragment ions. 
Collision energies were not applied for the TOF-MS method. The spectral scan time in 
each mode was 0.1 s and both TOF-MS and SONAR acquisitions were performed in 
sensitivity mode. The reference sprayer was sampled every 60 s and the data were lock-
mass corrected post-acquisition using leucine enkaphlin at 200 pg/µL. This provides a 
“snapshot” of the reference mass that can be used to perform exact mass measurements 
with a high degree of accuracy. 
 
3.3.6 Data processing 
 
All MS acquisitions were processed using Progenesis QI (Nonlinear Dynamics, 
Newcastle upon Tyne, United Kingdom) where samples were chromatographically 
aligned with respect to the mid-acquisition reference (QC3). Peak picked features were 
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statistically analysed using EZinfo (MKS Data Analytics Solutions, Umeå, Sweden) and 
the significant features of interest were imported back into Progenesis QI. 
Identifications were achieved whereby experimental fragments were matched against 
the theoretical fragmentation product ion spectra from LIPID MAPS (Lipidomics 
Gateway, United Kingdom). A mass tolerance of 10 ppm was applied for both precursor 
and product ions. The fragmentation scores and relative isotopic compositions of 
matched fragment ions derived from LIPID MAPS were used for structural elucidation 
and identification purposes. Additional manual annotation was also conducted using the 
Lipid Reporter toolkit and reported according to the shorthand nomenclature defined by 
Liebisch et al. (2013). 
 
3.3.7 Statistical analysis 
 
QC features with CV < 30% were applied for overall statistical analyses. Principal 
component analysis (PCA) and orthogonal projection to latent structures-discriminant 
analysis (OPLS-DA) were performed using EZinfo (Umetrics, Umeå, Sweden). The 
data were mean-centered and pareto-scaled prior to PCA and OPLS-DA. The features of 
interests were extracted from S-plots constructed following OPLS-DA analysis based on 
their contribution to the variation and correlation between the two groups (stable versus 
progressors). The variable importance in projection (VIP) scores of each feature was 
also calculated using the OPLS-DA model, and the features with VIP scores ≥ 1 were 
considered as significant (Bujak et al., 2016). The potential lipid features with p-value 
of less than 0.05 and VIP score of ≥ 1 were subjected to database searching against 
LIPID MAPS for fragment matching and lipid identification. 
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3.4 Results and Discussion 
 
Using the TOF-MS method, approximately 9,000 features in positive mode and 5,000 
features in negative mode were resolved in each analytical run. In comparison, SONAR 
detected 5,000 and 800 features for positive and negative mode respectively. Figures 3.1 
and 3.2 illustrate the sensitivity and selectivity of both the TOF-MS and SONAR 
acquisition methods by overlaying the total ion chromatograms (TIC) of a 
representative QC sample in positive and negative modes. Signal intensities of the TOF-
MS TICs were approximately five-fold (positive mode) and ten-fold (negative mode) 
greater than the TICs generated from SONAR. The TICs from the positive modes also 
displayed a typical lipid spectral pattern consistent with the work of Knittelfelder et al. 
(2014) and Cajka and Fiehn (2014). 
 
Figure 3.1 Overlaid total ion chromatograms of both TOF-MS (red) and SONAR 
(green) acquisitions in positive mode. The highlighted regions of the chromatogram 
illustrate the elution of lysophosphatidylcholine (LysoPC), 
lysophosphatidylethanolamine (LysoPE), phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), 
phosphatidic acid (PA), phosphatidylglycerol (PG), sphingomyelin (SM), diacylglycerol 
(DG), triglyceride (TG) and ceramide (Cer). 
LysoPC, 
LysoPE 
PC, PE, PS, PI, PA, PG, SM, DG 
TG, Cer 
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Figure 3.2 Overlaid total ion chromatograms of both TOF-MS (red) and SONAR 
(green) acquisitions in negative mode showing poor lipids resolution. 
 
 
Although the sensitivity of the SONAR method was lower than that of TOF-MS, the 
results showed good selectivity for SPLASH LipidoMix fragment ions. SONAR utilizes 
the scanning quadrupole technique to filter ions over the mass range of m/z 350 to 950 
and as a result, provided spectra with considerably less background (Moseley et al., 
2018). The selectivity and specificity of the method was further demonstrated where 
precursor ions from deuterium labelled-lipid standards were successfully extracted. 
Figure 3.3 represents the extracted ion chromatogram (XIC) of lipids in positive ion 
mode, showing that all lipid classes were equally resolved using both SONAR and 
TOF-MS. However, only four lipids were detected using SONAR in negative mode 
while nine lipids were detected by TOF-MS acquisitions (Figure 3.4).  
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Figure 3.3 The extracted ion chromatograms of spiked deuterium-labelled SPLASH 
LipidoMix standards in positive ion mode showing peaks corresponding to 15:0-
18:1(d7) PC, 15:0-18:1(d7) PE, 15:0-18:1(d7) PS, 15:0-18:1(d7) PG, 15:0-18:1(d7) PI, 
15:0-18:1(d7) PA, 18:1(d7) LysoPC, 18:1(d7) LysoPE, 18:1(d7) Chol Ester, 18:1(d7) 
MG, 15:0-18:1(d7) DG, 15:0-18:1(d7)-15:0 TG, 18:1(d9) SM and cholesterol (d7).  
 
 
 
Positive mode TOF-MS 
Cholesterol 
SM 
TG 
DG 
Chol Ester 
LysoPC 
LysoPE PA 
PG 
PI PC 
PS 
PE 
MG 
Positive mode SONAR 
Cholesterol 
SM 
TG 
DG 
Chol Ester 
LysoPC 
LysoPE PA 
PG 
PI 
PC 
PS 
PE 
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Figure 3.4 The extracted ion chromatograms of spiked deuterium-labelled SPLASH 
LipidoMix standards in negative ion mode showing peaks corresponding to 15:0-
18:1(d7) PC, 15:0-18:1(d7) PE, 15:0-18:1(d7) PS, 15:0-18:1(d7) PG, 15:0-18:1(d7) PI, 
15:0-18:1(d7) PA, 18:1(d7) LysoPE, 18:1(d7) Chol Ester and 18:1(d9) SM. 
 
 
 
 
 
Negative mode TOF-MS 
Negative mode SONAR 
LysoPE 
SM Chol Ester 
PA 
PI 
PS 
PG 
PE 
PC 
LysoPE 
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Features of interest from both the stable and progressor groups were then interrogated 
using Progenesis QI and EZinfo. To assess the contribution of experimental variability, 
QC samples were used for the filtration of features that experienced a variation 
coefficient higher than those measured in the QC data set (Calderón-Santiago et al., 
2017). The number of features in pooled QC samples with CV ≥ 30% were 3,716 and 
1,880 in positive mode TOF-MS and SONAR, and 969 and 402 in negative mode TOF-
MS and SONAR, respectively. A filter to remove these features were generated within 
the software and applied to all groups based on the acceptable bioanalytical variation 
limit of ≤ 30% relative standard deviation (Naz et al., 2014; Schoeman et al., 2018). 
PCA of QC samples were then applied to assess experiment quality. Figure 3.5 
illustrates the clustering of pooled QC samples in both positive and negative modes for 
TOF-MS acquisition and in negative mode for SONAR only. It was noted that the final 
two run-order QCs for the positive mode of SONAR did not cluster. Further evaluation 
of the raw data showed a rising baseline shift of the entire chromatogram from samples 
51 through to 66.  A rising baseline is typically observed in LC-MS acquisitions due to 
the systemic noise of gradient elution (Urban and Štys, 2015); however, it was possible 
that the total baseline shift observed was caused by detector drift (Yang et al., 2011). An 
increased chemical noise by the addition of new mobile phase or inconsistency in 
sample preparation can also contribute to the baseline shift but this was highly unlikely 
as the same extracted samples and mobile phases were used for both TOF-MS and 
SONAR acquisitions in both modes. 
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Figure 3.5 PCA score plots generated from all stable (ST, black), progressor (PR, red) and QC (QC, green) samples in all four modes of acquisition. 
The clustering of the pooled QC samples in each acquisition modes were shown encircled in green.  
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Using MatrixAnalyzer software (SpectralWorks Ltd, United Kingdom), the global 
intensities of QCs 5 and 6 acquired using SONAR in positive mode were shown to be 
considerably increased. A QC correction was then applied for sample intensities from 
injection number 50 to 60 to normalize the data (Figure 3.6). This normalization 
approach was based on the assumption that the QCs were technical replicates and that 
their intensities were independent of batch label and injection number (Wehrens et al., 
2016). The QC correction function from MatrixAnalyzer plug-in (Hill and Roessner, 
2013; Tolstikov et al., 2014) was then applied to improve data normalisation. In line 
with Wehrens et al. (2016), the corrections for this study were based only on features 
present within QC pooled samples. 
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Figure 3.6 Global sample projection of positive SONAR showing an overall intensity of uncorrected data for QCs 5 and 6 (circled), and normalised 
intensity post-correction using the MatrixAnalyzer tool. Correction lines (dotted blue) were fitted through the QCs and the samples and QCs were 
represented by the red and blue dots. 
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For statistical analysis, PCA was initially performed to decompose the stable and 
progressive patient dataset; however, unsupervised multivariate analysis did not reveal 
significant differences between both groups. The heterogenous nature of the grouping 
between these two diseased datasets supported similar assumptions made by Chang and 
Keinan (2014) where diseases with similar underlying mechanisms were more likely to 
cluster together in a principal component space. Supervised multivariate data analysis 
OPLS-DA was then used to generate a biased regression model to disentangle group-
predictive and group-unrelated variation in the measured data (Worley and Powers, 
2016). The OPLS-DA model clearly distinguished the stable and progressor groups and 
a scores plot (S-plot) was then generated. An S-Plot is a statistical tool for visualizing 
both the covariance and correlation between the endogenous features and the modelled 
group designation (ST versus PR). The S-Plot is useful for the identification of 
biochemically atypical features with statistical significance based on both the 
contributions to the model and their reliabilities (Dong et al., 2017). 
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Figure 3.7 OPLS-DA and S-plots comparing stable versus progressors plasma samples 
in positive mode TOF-MS (A), negative mode TOF-MS (B), positive mode SONAR 
(C) and negative mode SONAR (D). The ten features of interest in each group (circled) 
were exported into Progenesis QI software for identification. 
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By consolidating the S-plots from the OPLS-DA model as well as features with VIP 
scores ≥ 1, the top 10 features of interest in each group were exported into Progenesis 
QI software for identification. The differential features between the groups were 
analysed and database searched against LIPID MAPS. From the 20 features exported 
using EZinfo, 15 lipids from positive TOF-MS, 11 lipids from negative TOF-MS and 11 
lipids from positive SONAR mode were putatively identified. Negative mode SONAR 
experiment did not yield metabolite identifications with sufficient stringencies. 
 
The spiked deuterium-labelled SPLASH LipidoMix standards were then used to 
confirm the identity of putative lipids based on their retention times and m/z values. The 
TOF-MS experiments were successful at resolving the lipid classes chromatographically 
as shown in Figures 3.3 and 3.4; however, compound identification was still challenging 
due to the lack of precursor-product assignments. A number of features were not 
successfully resolved (Table 3.1). In particular, phosphatidylethanolamine (PE) and 
phosphatidylcholine (PC) were indistinguishable for a number of putative features; this 
was a commonly encountered problem with phospholipids due to the large number of 
structural isomers (Godzien et al., 2015). Resolving lipids chromatographically by class 
may aid in identification; however, with TOF-MS where no quadrupole isolation occurs, 
co-eluting species can still be challenging (Gethings et al., 2017). The precursor and 
product ions generated by SONAR contributed to the specificity of the method by 
providing additional MS/MS information for structural elucidation, and therefore 
increased the probability of successful lipid library matching (Satomi et al., 2017; 
Gethings et al., 2017). The advantages of SONAR DIA is evident in positive mode 
where each triglyceride (TG) was accurately identified by matching the generated 
fragmentation pattern with the theoretical product ion spectra from LIPID MAPS with > 
90% probability scores. Putative lipid identifications were annotated using the 
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shorthand nomenclature defined by Liebisch et al. (2013) that builds upon the current 
LIPID MAPS terminology. 
 
In addition to the successful identification of the lipid species, the relative quantitation 
of lipids identified was also achieved using known amounts of spiked deuterium-
labelled standards. The quantitative values were calculated by comparing the 
chromatographic peak area of each analyte to the peak area of the internal standard of 
the representative lipid class (Table 3.1). All other related statistics are presented in the 
Supplementary Table 3.1. 
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Table 3.1 Table showing the plasma lipids that were identified for stable and 
progressors of IPF through different acquisition modes and their associated fold changes. 
 
MS mode Feature 
m/z 
Putative 
ID 
Stable Progressor Fold Changes 
mmol/L mmol/L 
Positive  
TOF-MS 
820.7382 TG [48:2] 1.29 1.22 0.95 
      
 524.3730 PE [21:0] 0.01 0.37 0.90 
  PC [18:0] 33.46 29.99  
  PC [O-18:0]    
      
 879.7440 TG [52:3] 0.98 1.05 1.08 
      
 924.8041 TG [56:6] 0.56 0.63 1.11 
      
 794.7233 TG [46:1] 0.46 0.43 0.92 
      
 920.7704 TG [56:8] 0.52 0.66 1.27 
      
 822.7558 TG [48:1] 0.62 0.58 0.95 
      
 951.7406 TG [58:9] 0.07 0.10 1.38 
      
 788.6164 PC [36:1] 60.63 56.68 0.93 
  PE [39:1] 0.01 0.69  
      
 834.5986 PC [40:6] 16.42 13.80 0.84 
  PE [43:6] 0.01 0.17  
      
 784.5851 PC [36:3] 59.40 57.57 0.97 
  PE [39:3] 0.01 0.71  
      
 878.8198 TG [52:1] 1.00 0.98 0.98 
      
 812.6164 PC [38:3] 44.66 39.08 0.88 
  PC [36:0]    
  PE [39:0] 0.01 0.49  
  PE [41:3]    
  PA [43:4] 1.07 0.94  
      
 785.5885 PA [O-40:0] 1.10 1.04 0.94 
      
 881.7600 TG [54:5] 0.92 0.98 1.06 
  TG [52:2]    
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Negative 
TOF-MS 
856.6105 PS [41:2] 0.07 0.06 0.83 
 768.5570 PC [35:3] 13.41 11.88 0.89 
  PE [38:3] 0.01 0.01  
 828.5780 PS [39:2] 0.16 0.14 0.89 
      
 480.3094 PE [18:0] 0.02 0.01 0.85 
  LysoPE [18:0] 0.60 0.51  
  PC [15:0] 17.66 14.95  
      
 832.6102 PS [39:0] 0.08 0.07 0.87 
      
 830.5927 PS [39:1] 0.34 0.31 0.90 
      
 770.5717 PC [35:2] 26.37 23.78 0.90 
  PE [38:2] 0.03 0.02  
  PS [O-37:1] 0.13 0.12  
  PS [P-37:0]    
      
 797.6063 PG [O-40:2] 0.36 0.37 1.01 
  PG [P-40:1]    
  PA [43:2] 0.08 0.08  
  TG [50:9] 30.35 30.70  
      
 802.5605 PS [37:1] 0.50 0.48 0.95 
      
 885.5519 PI [38:4] 0.05 0.05 0.84 
      
Positive 
SONAR 
923.7138 TG [56:9] 0.04 0.05 1.37 
 868.7379 TG [52:6] 
 
0.10 0.10 1.01 
 894.7547 TG [54:7] 
 
0.38 0.42 1.09 
 920.7718 TG [56:8] 
 
0.99 1.19 1.21 
 896.7703 TG [54:6] 
 
0.20 0.21 1.04 
 922.7879 TG [56:7] 
 
0.81 0.89 1.09 
 603.5333 DG [O-34:1] 
 
n/a n/a 1.09 
 784.5847 PC [36:3] 
 
136.01 132.54 0.97 
 806.5665 PC [36:3] 49.84 44.75 0.90 
 808.5829 PC [36:2] 
 
118.50 108.08 0.91 
 812.6160 PC [38:3] 
 
100.89 80.86 0.80 
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3.4.1 Lipid markers correlated to IPF 
 
Abnormal lipid metabolism has been shown to result in lung diseases including asthma 
(Zehethofer et al., 2015; Yuan et al., 2018) and COPD (Higham et al., 2012; Naik et al., 
2014). However, its potential role in IPF pathogenesis remains unclear. In this study, a 
scanning DIA technique facilitated improved lipid identification of a number of spiked 
lipid standards. In addition, the lipid profiles from 30 patients diagnosed with 
progressive IPF showed changes in lipid plasma composition when compared to the 30 
stable subjects. The fold changes calculated revealed minimal variability (+/- 20%) in 
levels of the identified lipids between the two groups. This was expected as both groups 
were derived from diseased individuals. Healthy controls were not included in this study 
as the aim was to investigate the ability of the DIA technique to discriminate plasma 
lipid differences between diseased groups only.  
 
Using SONAR, a number of triglycerides (TG), diglyceride (DG) and PCs that were 
unique lipid markers of IPF progression were identified and this was shown to be 
consistent with the findings of Hu et al. (2015) and Yan et al. (2017). The levels of 
these TGs (56:9, 54:7, 56:8 and 56:7) and DG (O-34:1) appeared to be elevated while 
PCs (36:3, 36:2 and 38:3) was reduced in the samples of progressors compared to stable 
patients.  A recent study by Yan et al. (2017) showed that 6 DGs (16:0/18:1/0:0, O-
16:0/18:1, 18:0/18:2/0:0, 16:0/18:2/0:0, 18:1/18:3/0:0 and 18:1/18:2/0:0) and 9 TGs 
(16:0/18:2/18:2, 16:0/18:1/18:2, 16:0/18:1/20:3, 16:0/18:3/20:0, 16:0/16:1/18:1, 
18:4/20:3/22:0, 17:0/18:1/19:1, 18:1/20:3/20:4 and 16:0/20:3/20:5) were found to be 
increased while 13 PCs (22:6/16:0, 16:0/18:2, 0:0/16:0, 22:4/18:2, 20:2/18:2, 18:1/18:1, 
18:0/18:1, 18:0/0:0, 22:6/18:2, 20:3/P-18:1, 20:5/0:0 and 17:0/19:1) were  decreased in 
IPF patients compared to healthy control subjects. Using a bleomycin mouse model of 
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pulmonary fibrosis, Kulkarni et al. (2018) observed a four-fold upregulation of DG but 
showed unchanged levels of TG. Both DGs and TGs are the most abundant lipids found 
in circulating plasma (Ishikawa et al., 2016; Tham et al., 2018) and are important 
bioactive mediators of cell membranes (Yan et al., 2017; Dautel et al., 2017). DG is not 
only an important source of free fatty acids but is also a precursor for the synthesis of 
more complex lipids. The conversion of phosphatidic acid into DG is crucial for the 
synthesis of PC, PE, and phosphatidylserine (PS; Sarri et al., 2011; Ferraz-Nogueira et 
al., 2014). DG synthesis has been shown to be implicated in several lung diseases 
including cystic fibrosis (Aureli et al., 2016), asthma and COPD (Hichami et al., 2005) 
as well as IPF (Hu et al., 2015).  
 
TG was only found to be elevated in smokers with exacerbated COPD suggesting a 
causal effect of smoking on the inhibition of lipoprotein lipase by nicotine (Titz et al., 
2016). Lipoprotein lipase activity is rate limiting for the removal of TG from the 
circulation of blood. Pro-inflammatory cytokines such as tumour necrosis factor α 
(TNF-α) are known to be mediators of hyperlipidemia in infection and in severe stress 
because they both inhibit lipoprotein lipase activity (Popa et al., 2007). We 
hypothesised that the TG clearance was decreased due to the inhibition of lipoprotein 
lipase activity thereby stimulating lipogenesis. Although cytokine concentrations were 
not measured, Figueroa et al. (2002) speculated that hypertriglyceridemia (elevated TG) 
in cystic fibrosis patients may be positively correlated with TNF-α concentrations. 
 
Changes in phospholipids such as PCs in lung diseases have been reported since the late 
80s in animal models of rapidly developing pulmonary fibrosis (Baker et al., 1986; Low, 
1989). Guerrera et al. (2009) revealed significant decrease in plasma PCs in cystic 
fibrosis patients using matrix-assisted laser desorption (MALDI)-TOF experiment. This 
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study also suggested that a decrease in PCs levels by 20% may be correlated with the 
progression of disease. This decrease is further supported by Yan et al. (2017) who also 
found lower levels of plasma PCs in patients with IPF.  PCs are lipids that incorporate 
choline as head group and form the most abundant component in the outer leaflet of the 
cell membrane (Nicolson and Ash, 2014; Pöyry and Vattulainen, 2016). Phospholipase 
A2 converts phospholipids into lysophosphatidic acid and arachidonic acid via 
hydrolysis (Yamamoto et al., 2011), which are then modified into eicosanoids that 
include proinflammatory mediators such as prostaglandins and leukotrienes (Yui et al., 
2015). Bleomycin-induced overproduction of proinflammatory cytokines such as 
thromboxane and leukotrienes are significantly reduced in mice with phospholipase 
inhibition, implicating a direct role for phospholipase as well as a putative role for PC in 
the pathogenesis of pulmonary fibrosis (Zhu et al., 2010; Cheng et al., 2015). The 
surfactant proteins SP-B and SP-C as well as phospholipid PCs are key components of 
lung surfactant produced by alveolar epithelial cell type 2 (Han and Mallampalli, 2015). 
An alteration in the composition of lung surfactants which are predominantly comprised 
of PCs can cause reduced elasticity and lead to an overall decrease in lung compliance. 
However, our findings were in contrast to those of Kulkarni et al. (2018), who reported 
a marked increase of approximately two-fold in the relative content of PCs (12:0/20:4, 
18:2p/15:1, 16:1p/15:1, 15:1/20:4, 18:0e/20:4, 4:0/19:0, 24:6/24:7, 16:0e/20:4, 
16:1/20:4, 16:1p/13:0, 15:0/20:4, 18:0/19:1, 16:0p/18:2, 16:1/18:2, 18:1/18:2, 
18:0p/18:2, 22:6/24:7, 16:0e/18:2 and 18:0/18:1) in bleomycin-treated mice. Previous 
interstitial lung disease studies comparing IPF and sarcoidosis revealed a reduced 
amount of saturated fatty acids, in particular palmitic acids in the PC fraction of 
bronchoalveolar lavage. This supported our finding of decreased levels of PCs in IPF 
progressors (Honda et al., 1988; Schmidt et al., 2002).  
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Negative TOF-MS data revealed a number of lipid species such as PE (38:3, 18:0 and 
38:2), PS (41:2, 39:2, 39:0, 39:1 and 37:1) and phosphatidylinositol (PI; 38:4). The 
down-regulation of these lipids in the progessors of IPF lent further support to Yan et al. 
(2017) observations of reduced PE (20:0/17:2 and 22:6/19:0), PS (20:0/19:0, 22:0/0:0, 
0-20:0/20:0 and P-18:0/19:0) and PI (Cer d20:0/16:0) levels. PE is the second most 
abundant phospholipid in biological membranes and along with PC forms the 
hydrocarbon-backbone linkage of most cell membranes. PE is crucial for cell division 
as PE deficient cells show abnormal mitochondrial morphology and are unable to 
complete cell division and separate. However, studies by Poyton et al. (2016) and 
Calzada et al. (2016) reported that an increase in cellular PE leads to increased lipid 
oxidation, a common hallmark in neurological diseases. A separate study by Fahrmann 
et al. (2016) showed evidence of elevated PE (34:2, 36:2 and 38:4) as important 
biomarkers to distinguish between malignant and benign lung cancers. Although PS and 
PI are not as well understood as PC and PE, their elucidation using negative TOF-MS 
warrants further investigation. These phospholipid classes are associated with 
inflammation and cellular apoptosis and may be associated with IPF and its severity. 
 
A potential limitation in this study was the small cohort size. Nevertheless, the 
availability of the two diseased sample groups (stable versus progressors) allowed us to 
study global lipid changes associated with disease progression. The selectivity of the 
SONAR DIA approach was highlighted in this study using the deuterium-labelled lipid 
standards that were representative of the different classes of lipids found in human 
plasma. The isolation of the molecular ions prior to fragmentation allowed fragment 
ions to be easily assigned to its relevant precursors for specific compound identification 
(Gethings et al., 2017). Although the sensitivity of SONAR was lower than the TOF-
MS acquisition, a reduction in the total number of features resolved generated cleaner 
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lipid spectra and less interferences (Meyer and Schilling, 2017). Another advantage of 
SONAR is that the data generated were significantly smaller in size compared to other 
acquistion data files. This has considerable operational and resource benefits in terms of 
data processing, handling and storage. 
 
3.5 Conclusion 
 
This project successfully profiled plasma samples obtained from two groups of IPF 
patients using a DIA approach to enhance the specificity of unbiased lipid profiling 
derived from UPLC-QTOF-MS. In particular, this study demonstrated the advantages of 
the SONAR DIA technique for the characterization of lipid signatures such as TGs and 
PCs in IPF plasma samples. The use of labelled lipid internal standards allowed for the 
identification and quantitation of markers involved in pathways associated with disease 
pathogenesis such as lipid metabolism and mitochondrial-beta oxidation pathways. 
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Supplementary Table 3.1 Progenesis output of the features detected including m/z, chemical formula, mass error, putative identification (ID) as well as 
the calculated mean abundance, percentage relative standard deviation (%RSD), fold-changes and the relative concentrations based on the SPLASH 
LipidoMix standards.  
 
MS 
mode 
Feature Chemical Mass 
error 
Putative Stable (ST) Progressor (PR) 
 m/z Formula ppm ID Mean  %RSD Concentration 
(mmol/L) 
Mean  %RSD Concentration 
(mmol/L) 
Fold-
Change 
Positive 
TOF-MS 
820.7382 C51H94O6 -5.70 TG 
[48:2] 
3922230.27 35.27 1.29 3708641.14 43.31 1.22 0.95 
            
 524.3730 C26H54NO7P 3.69 PE 
[21:0] 
1181324.53 28.33 0.01 1058805.34 23.63 0.37 0.90 
  C26H54NO7P 3.69 PC 
[18:0] 
  33.46   29.99  
  C26H54NO7P 3.69 PC [O-
18:0] 
       
            
 879.7440 C55H100O6 -1.47 TG 
[52:3] 
3162371.36 20.35 0.98 3411677.49 10.60 1.05 1.08 
            
 924.8041 C59H102O6 3.20 TG 
[56:6] 
1938446.34 30.97 0.56 2161005.90 22.05 0.63 1.11 
            
 794.7233 C49H92O6 -4.82 TG 
[46:1] 
1359110.87 43.81 0.46 1252028.51 66.42 0.43 0.92 
            
 920.7704 C59H98O6 7.12 TG 
[56:8] 
1787751.49 42.00 0.52 2264408.98 31.17 0.66 1.27 
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 822.7558 C51H96O6 1.60 TG 
[48:1] 
1876332.83 33.05 0.62 1779940.41 36.50 0.58 0.95 
            
 951.7406 C61H100O6 -0.62 TG 
[58:9] 
257870.68 32.51 0.07 354931.15 36.26 0.10 1.38 
            
 788.6164 C44H86NO8P -0.02 PC 
[36:1] 
3221172.70 30.93 60.63 3011316.08 23.61 56.68 0.93 
  C44H86NO8P -0.02 PE 
[39:1] 
  0.01   0.69  
            
 834.5986 C48H84NO8P -2.55 PC 
[40:6] 
923395.13 38.88 16.42 776133.27 35.49 13.80 0.84 
  C44H83NO13 5.86 PE 
[43:6] 
  0.01   0.17  
            
 784.5851 C44H82NO8P -0.02 PC 
[36:3] 
3139547.70 26.30 59.40 3043281.89 26.72 57.57 0.97 
  C44H82NO8P -0.02 PE 
[39:3] 
  0.01   0.71  
            
 878.8198 C55H104O6 3.16 TG 
[52:1] 
3250208.57 31.44 1.00 3183352.66 26.92 0.98 0.98 
            
 812.6164 C46H86NO8P 0.01 PC 
[38:3] 
2445269.59 35.04 44.66 2139828.78 30.90 39.08 0.88 
  C44H88NO8P 3.06 PC 
[36:0] 
       
  C44H88NO8P 3.06 PE   0.01   0.49  
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[39:0] 
  C46H86NO8P 0.01 PE 
[41:3] 
       
  C46H83O8P 0.01 PA 
[43:4] 
  1.07   0.94  
            
 785.5885 C43H87O7P 8.54 PA [O-
40:0] 
2362037.61 28.48 1.10 2219762.12 24.44 1.04 0.94 
            
 881.7600 C57H100O6 0.81 TG 
[54:5] 
3077766.22 20.66 0.92 3257735.02 8.23 0.98 1.06 
  C55H102O6 3.63 TG 
[52:2] 
       
            
Negative 
TOF-MS 
856.6105 C47H88NO10P 1.31 PS [41:2] 74416.05 25.10 0.07 62036.87 35.15 0.06 0.83 
            
 768.5570 C43H80NO8P 1.45 PC 
[35:3] 
67730.51 18.77 13.41 60031.62 30.03 11.88 0.89 
  C43H80NO8P 1.45 PE 
[38:3] 
  0.01   0.01  
            
 828.5780 C45H84NO10P 2.59 PS [39:2] 165448.74 18.33 0.16 147108.90 29.87 0.14 0.89 
            
 480.3094 C23H48NO7P -0.24 PE 
[18:0] 
55791.69 17.18 0.02 47244.98 30.48 0.01 0.85 
  C23H48NO7P -0.24 LysoPE 
[18:0] 
  0.60   0.51  
  C23H48NO7P -0.24 PC   17.66   14.95  
 Chapter 3 
 
117 
 
[15:0] 
            
 832.6102 C45H88NO10P 3.49 PS [39:0] 86008.62 22.56 0.08 74745.40 28.41 0.07 0.87 
  C46H87NO9 3.43         
            
 830.5927 C45H86NO10P 1.24 PS [39:1] 359209.72 10.82 0.34 324924.30 29.37 0.31 0.90 
            
 770.5717 C43H82NO8P 1.57 PC 
[35:2] 
133594.03 12.05 26.37 120452.91 30.95 23.78 0.90 
  C43H82NO8P 1.57 PE 
[38:2] 
  0.03   0.02  
  C43H84NO9P 1.53 PS [O-
37:1] 
  0.13   0.12  
  C43H84NO9P 1.53 PS [P-
37:0] 
       
  C43H82NO8P 1.57 PE-
NMe2 
[36:2] 
       
  C44H81NO7 1.40 DGTS 
[34:2] 
       
            
 797.6063 C46H89O9P -0.34 PG [O-
40:2] 
67610.32 10.95 0.36 68389.40 22.07 0.37 1.01 
  C46H89O9P -0.34 PG [P-
40:1] 
       
  C46H87O8P -0.35 PA 
[43:2] 
  0.08   0.08  
  C53H84O6 -3.24 TG 
[50:9] 
  30.35   30.70  
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 802.5605 C43H82NO10P 0.20 PS [37:1] 515132.53 10.28 0.50 487701.69 27.47 0.48 0.95 
  C43H82NO10P 0.20 PT 
[36:1] 
       
            
 885.5519 C47H83O13P 2.36 PI [38:4] 154232.67 22.78 0.05 129368.60 29.20 0.05 0.84 
  C47H83O13P 2.36 Glc-GP 
[38:4] 
       
            
Positive 
SONAR 
923.7138 C57H102O6 2.55 TG 
[56:9] 
3076.29 62.00 0.04 4224.01 81.20 0.05 1.37 
 868.7379 C55H96O6 1.21 TG 
[52:6] 
7640.05 86.83 0.10 7706.59 72.50 0.10 1.01 
 894.7547 C57H98O6 -4.19 TG 
[54:7] 
30733.15 69.55 0.38 33646.03 63.16 0.42 1.09 
 920.7718 C56H94O6 9.16 TG 
[56:8] 
81674.38 51.30 0.99 98617.58 45.81 1.19 1.21 
 896.7703 C57H100O6 1.73 TG 
[54:6] 
16442.49 61.27 0.20 17179.25 55.30 0.21 1.04 
 922.7879 C55H104O6 2.18 TG 
[56:7] 
67636.37 38.61 0.81 74015.93 51.46 0.89 1.09 
 603.5333 C37H72O4 1.83 DG [O-
34:1] 
69975.54 46.43 n/a 76449.96 65.02 n/a 1.09 
 784.5847 C44H78NO8P -1.12 PC 
[36:3] 
354079.28 29.03 136.01 345040.15 39.73 132.54 0.97 
 806.5665 C46H82NO8P -1.44 PC 
[36:3] 
129744.46 25.50 49.84 116483.47 39.00 44.75 0.90 
 808.5829 C44H84NO8P -0.64 PC 
[36:2] 
309271.88 24.07 118.50 282083.51 31.34 108.08 0.91 
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 812.6160 C46H86NO8P -0.19 PC 
[38:3] 
272053.56 33.73 100.89 218044.34 43.11 80.86 0.80 
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MALDI-mass spectrometry imaging by freeze-spot deposition of the matrix 
 
Adapted from Nambiar, S.; Trengove, R. D..; and Gummer, J. P. A (2018) “MALDI-
mass spectrometry imaging by freeze-spot deposition of the matrix” Ready for 
submission to Analytical Chemistry 
 
4.1 Abstract 
 
Imaging mass spectrometry is emerging as a powerful tool for the visualisation of 
metabolite distribution as well as the measurement of metabolites without the loss of 
spatial dimensionality in a sample. In MALDI-MSI, deposition of the chemical-matrix 
onto the sample serves to simultaneously extract biomolecules to the sample surface and 
concurrently render the sample amenable to MALDI. However, the mechanism of 
matrix application can mobilise the metabolites and together with the matrix-crystal size 
formation limit the spatial resolution which may otherwise be achieved by MSI. The 
chosen method of matrix deposition is thus integral to maintaining the spatial 
dimensionality endogenous to a sample. Here, we described a matrix application 
technique, herein referred to as the “freeze-spot” method. The method was conceived as 
a low-cost preparative approach requiring minimal amounts of chemical matrix which 
maintains the spatial dimensionality of the sample for MALDI-MSI. Matrix deposition 
is achieved by spot or spray application of the matrix solution, solubilised within an 
organic solvent with a freezing step using a chilled sample stage to which the sample 
section is mounted. The matrix solution freezes upon contact with the sample and the 
solvent is removed by lyophilisation. The technique was found to be particularly useful 
for MALDI-MSI of small sample sections and is well suited to efficient and cost-
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effective method development whilst maintaining the spatial dimensionality that 
traditional spotting methods lack.   
 
Keywords: MALDI, MSI, matrix, freeze-spot, adduct  
 
4.2 Introduction 
 
Mass spectrometry imaging (MSI) is a powerful tool for the measurement of 
metabolites which captures the spatial dimensionality of metabolite distribution of a 
sample. MSI has wide-ranging application in all areas of biological (Rompp et al., 
2015), biomedical (Liu and Ouyang, 2013), clinical research (Addie et al., 2015) and 
diagnostics (Ye et al., 2013; Norris et al., 2017), with a diversity of dedicated sample 
preparative approaches. MSI is performed by positioning the sample within a purpose-
build ion source of a mass spectrometer, whereby the ionisation process which starts 
from a single focal point of the sample is then rastered across the sample surface and a 
mass spectrum generated at each pixel coordinate. These mass spectra can be assembled 
into an ion-map image representing the relative signal intensity and spatial distribution 
of the measured biomolecular species co-registered to the original sample section. From 
sample collection through to MS acquisition, MSI experiments require a number of key 
preparative steps which serve to influence the final interpretative outcome and are 
therefore worthy of careful consideration. Each has been well described in the literature 
(McDonnell and Heeren, 2007; Amstalden van Hove et al., 2010) as well as in a recent 
systematic review by Boughton et al. (2016). 
 
Matrix-assisted laser desorption ionisation (MALDI) continues to dominate as the most 
common ionisation mechanism in MSI (Boughton and Hamilton, 2017). A key step in 
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preparing a sample for MALDI-MSI is application of the chemical matrix (Vergeiner et 
al., 2014), and consequently, consideration of the choice of MALDI matrix and methods 
for its deposition onto a sample are critical. A uniform matrix application is crucial to 
extract and desorb molecules efficiently from within the section, to the sample surface. 
Uneven matrix deposition may result in sample coordinates with less than desirable ion 
signal intensity due to insufficient amount of matrix, or biomolecule delocalization 
caused by excessive or lengthy contact with the solvated matrix (Gemperline et al., 
2014).  
 
Matrix application plays a critical role in the quality of the mass spectral images 
generated, specifically when aiming to achieve the highest spatial resolution images. 
The spatial dimensionality and reproducibility are limited by matrix crystal size 
(Gemperline et al., 2014), solvent composition (Li et al., 2016) and availability of 
elemental species which lend themselves to ion/adduct formation upon ionisation. 
Conventional methods for matrix application include the use of airbrush, automatic 
sprayer, and sublimation (Gemperline et al., 2014). These methods share a common 
goal of achieving small matrix crystal size formation and minimising contact with the 
liquid solvent.  Application of the matrix solution by airbrush spraying is commonly 
used in MALDI imaging and is relatively simple and quick, requiring relatively 
inexpensive apparatus (Gemperline et al., 2014; Li et al., 2016). The major limitation of 
this technique is that the sprayer and the velocity of the spray are controlled manually 
which causes the quality of the application to be user dependent and may greatly affect 
the reproducibility of data. Variations in the spray velocity and duration cause 
inconsistent application and applying too much solvent to the tissue can cause analyte 
delocalization, and predominantly of the small molecules (Baluya et al., 2007). 
Automatic sprayer systems, such as the TM-Sprayer from HTX Technologies, have 
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been developed to remove the variability seen with manual airbrush application by 
robotically controlling the temperature, solvent flow rate, velocity of the matrix 
spraying nozzle during each pass, and number of passes (Gemperline et al., 2014; Li et 
al., 2016). With appropriate optimisation of methodology an automatic sprayer system 
can achieve uniform matrix density and crystal size formation, and experimental results 
more reproducible. This specialised equipment however, is not always readily available 
to researchers. Recently, the solvent-free sublimation technique has gained popularity 
for MSI of small molecules (Gemperline et al., 2014; Van Nuffel et al., 2018). 
Sublimation reduces analyte diffusion because the matrix deposits onto the sample 
surface free of liquid solvent which may otherwise delocalize molecules within the 
sample (Van Nuffel et al., 2018). Murphy et al. (2011), Weishaupt et al. (2015) and 
Yang et al. (2017) previously reported that the formation of fine matrix crystals by the 
sublimation method translates to improved spatial measurements of the metabolites. 
However, one considered drawback of this method is if the liquid solvent does not make 
contact with the sample surface and thus not being available as an analyte extractant. 
This may result in some compound classes going undetected, though maintaining the 
superior spatial resolution of those that do. 
 
While these presently applied techniques are routinely used in MALDI-MSI, matrix 
deposition techniques such as the “dried droplet” method, achieved by simple pipette-
spotting, are still used when maintaining the spatial dimensionality. Traditionally in this 
approach the matrix solution is combined with the sample and spotted onto the target 
surface for analysis (Gabriel et al., 2014). The sample/matrix droplet is subsequently 
dried. This approach lends itself to rapid method optimisation by permitting small 
amounts of matrix solution of any desirable composition to be applied to a sample 
section for rapid screening. The ease and robustness of the method validates its more 
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recent application in studies involving peptide identification (Schlosser et al., 2009), 
lipid profiling (Murphy et al., 2011) and pharmocatherapy (Grove et al., 2011). 
However, the critical problems associated with this method is the sample preparation 
and the creation of “hot spots”, regions of relative high sample intensity. This is due in 
part to the uncontrolled matrix crystallisation. These “hot spots” present a major 
challenge to the detection and quantitation of analytes due to certain regions containing 
high intensity data while some regions may not have sufficient signal to generate a 
spectrum (Gabriel et al., 2014; Fukuyama et al., 2015).   
 
In this study, we introduce a novel matrix application technique coined “freeze-spot”. 
This technique was conceived as a low-resource-intensive matrix application for 
spatially small samples for MALDI-MSI. This method is hypothesised to improve the 
throughput of method optimisations whilst maintaining the spatial localisation of 
metabolites endogenous to the sample.  Matrix application is achieved by pipette-
spotting the matrix solution onto the sample which is mounted on a chilled sample stage. 
When using a relatively high freezing point solvent, the matrix solution freezes upon 
contact with the sample and the solvent is then removed by lyophilisation. The “freeze-
spot” method was found to be quick, cost-effective; requiring minimal amounts of 
chemical matrix, quantitative; with data not suffering from hot spots, and with the 
spatial resolution of the acquired MALDI-MS image maintained. 
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4.3 Experimental section 
 
4.3.1 Chemicals  
 
Ultra-pure LC-MS grade solvents including acetonitrile (ACN), isopropanol (IPA) and 
water (H2O) as well as trifluoroacetic acid (TFA) were purchased from Thermo Fisher 
Scientific (Massachusetts, USA). Sodium acetate (NaOAc), potassium acetate (KOAc) 
and 2,5-dihydroxybenzoic acid (DHB) were obtained from Sigma-Aldrich (Castle Hill, 
Australia) and used without further purification. 
 
4.3.2 Sample preparation 
 
The technique is demonstrated using wheat seed. Wheat seed sections were embedded 
in boiled-egg white matrix as recently described in Bøgeskov Schmidt et al. (2018). 
Briefly, commercial chicken eggs were boiled, and the denatured egg white composed 
of albumin was collected. Wheat seedlings of the Chara cultivar were harvested directly 
from the plant and embedded in a 2 cm cube of denatured albumin. The albumin block 
was then gently frozen by placing it directly above liquid nitrogen, and subsequently 
mounted to a cryotome chuck using an optimal cutting temperature (OCT) compound. 
Wheat seeds were cryo-sectioned at -20 °C and at 20 µm thickness, taking care to avoid 
OCT material contact with the sectioned tissue. The seed sections were transferred onto 
pre-chilled glass microscope slides by thaw-mounting. All microscopy glass slides were 
thoroughly rinsed with IPA and chilled in the cryotome prior to sample mounting. All 
sections were stored at -80 °C. 
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4.3.3 Matrix application 
 
To prepare for matrix application, the same sections were lyophilised to dryness under 
vacuum of approximately 50 Torr for 30 mins using a Labconco Freezone 2.5 Plus 
freeze-dryer depressurized with a JLT-10 JAVAC high vacuum pump.  
 
For freeze-spot matrix application, DHB matrix was prepared at a concentration of 20 
mg/mL in 80 % ACN (0.1 % TFA). Where reported, the matrix solution also contained 
10 mM of either sodium acetate (NaOAc) or potassium acetate (KOAc), to promote 
sodium ([M+Na]+) or potassium ([M+K]+) adduct formation, respectively. The mounted 
sample sections were placed onto a stainless-steel stage, pre-chilled on dry ice and 5 µL 
DHB (20 mg/mL) matrix was transferred onto the sample section by pipette. The 
solvent immediately froze upon contact with the sample. The glass slides were 
transferred to a polypropylene 50-mL centrifuge tube, which was sealed, submerged 
briefly in liquid nitrogen and the solvent removed by lyophilisation. 
 
Similarly, DHB matrix prepared at 20 mg/mL in 80 % ACN (0.1 % TFA) was also used 
for the dried droplet and the automated matrix application techniques. For the dried-
droplet approach, 5 µL of DHB was pipetted onto the lyophilised section and the matrix 
droplet was left to dry for 15 mins at room temperature. For the automated approach, a 
TM-Sprayer (HTX Technologies; North Carolina, U.S.A.) fitted with a Shimadzu 
LC20-AD HPLC pump (Shimadzu Australia, New South Wales, Australia) was utilised. 
The sample loop was filled with 6 mL of DHB matrix solution and deposited onto the 
section using a flow rate of 0.25 mL/min; spray nozzle temperature and velocity at 
110 °C and 700 mm/min, respectively, with four passes at 2 mm spacing, followed by 
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alternate passes at 90° offset. Slides from both the dried droplet and automated 
approaches were then placed in the freeze-dryer for lyophilisation. 
 
4.3.4 Microscopy 
 
The dimensional distribution of the DHB crystals formed under different matrix 
application techniques were examined by optical microscopy using an Olympus BX51 
(Olympus Australia Pty Ltd, Victoria, Australia) with an objective magnification of 40x 
and sensitivity set at ISO200. Microscopy images were acquired using an “auto” 
exposure mode with an exposure time of 1/2,000 s at 50 µm scale. 
 
4.3.5 MALDI-MSI acquisition 
 
All MALDI-MSI analyses were performed using a Waters Synapt G2S mass 
spectrometer equipped with an orthogonal MALDI ion source and Nd:YAG laser 
(Waters Corporation, Manchester, U.K.). Prior to the analytical acquisition, digital scans 
of the tissue sections were obtained using an Epson WorkForce Pro WP-4540 scanner 
(Epson America, Inc.) and imported into the MALDI Imaging Pattern Creator software 
(Waters Corporation, Manchester, UK). Data were acquired from the selected regions of 
interest using positive ionisation mode, operating at a 350 J laser energy, with a 1,000 
Hz firing rate. All data were acquired over the mass range m/z 50 to 1,200 using an 
“automatic” scan speed setting.  Raw signal intensities of the mass spectra were 
extracted using MassLynx version 4.0 (Waters Corporation, Manchester, UK). The MSI 
images were acquired at a spatial resolution set at 600 laser shots per position and ion 
images were generated with Biomap 3.7.5.5 software. 
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4.4 Results and Discussion 
 
Mass spectrometry imaging approaches typically require optimization for each 
parameter, including the screening of appropriate matrix application techniques. The 
initial work was focused on the uniformity of matrix deposition across a microscopy 
glass slide. Three commonly used technique, automatic sprayer and manual spotting, 
along with the newly developed freeze-spot method, were employed using the prepared 
DHB matrix at 20 mg/mL.  
 
The freeze spot approach performed comparably to deposition of matrix by automatic 
spray application, whilst manual spotting lacked uniformity and inconsistency in 
application (Figure 4.1). Chemical matrices can be applied in a controlled manner using 
an automated device to spray the matrix onto the sample in a programmable way. 
Commercially available automatic sprayers although differing in mechanism, use the 
same basic principle of spraying a fine aerosol of matrix which deposits onto the surface 
of the sample (Mounfield and Garrett, 2012). Multiple offset spray coats were required 
to deposit enough of the chemical matrix to sufficiently cover the section of interest 
(Figure 4.1), which made this more time intensive and a more chemical matrix-
consuming approach to the freeze spot. The advantage of this automatic system over the 
manual approach is to achieve reproducibility in application, particularly of large 
sample sections, with another benefit that the conditions of coating can be adjusted in a 
systematic way to optimize the coating procedure for the given sample tissue 
(Gemperline et al., 2014).  
 
Manual spotting of chemical matrices has the advantage that it is inexpensive and easy 
to implement. Earlier studies have used this approach to coat specific sample regions of 
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interest with the matrix, for a focussed MSI acquisition. For the trained user, this 
technique can be used to generate very high-resolution images of the tissue; however, 
the major disadvantage of manual spotting is that it is user dependant and it is difficult 
to standardize across multiple samples (Figure 4.2; Gemperline et al., 2014). Matrix is 
deposited directly onto the tissue and then allowed to dry. Each of these demonstrated 
manual spot applications (Figure 4.1) were performed with a single pipetting step, and 
with just 5 µL of DHB. The spotting techniques were further investigated to understand 
the resultant matrix crystal formation and uniformity (Figure 4.2). 
 
 
 
Figure 4.1 The different matrix application approaches using DHB prepared at 20 
mg/mL. (A) Automatic sprayer; (B) manual spotting with an ambient dry-out step; (C) 
manual spotting on dry ice followed by a dry-out step; and (D) freeze-spotting 
technique. 
 Chapter 4 
 
130 
 
The capture of phase-contrast images (Yin et al., 2012) by conventional light 
microscopy allowed the morphology of the matrix crystals to also be examined (Figure 
4.2). Crystallisation of the DHB matrix after deposition by automatic sprayer (Figure 
4.2; A) was compared to deposition by manual spotting; one was dried at room 
temperature and the other on dry ice, respectively (Figure 4.2; B, C).  The matrix 
crystals formation using the freeze-spot approach is also presented for comparison 
(Figure 4.2; D). A comparatively fine “web” of crystals was observed using the freeze-
spot approach, which together with the observed depth of matrix presented a far more 
homogeneous application (Figures 4.1 and 4.2). 
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Figure 4.2 Light microscopic images of the matrix crystals obtained by the different 
application approaches using DHB prepared at 20 mg/mL. (A) Automatic sprayer; (B) 
manual spotting with an ambient dry-out step; (C) manual spotting on dry ice followed 
by a dry-out step; and (D) freeze-spotting technique. 
 
 
 
 
 
 
 
A B 
C D 
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Direct application of the chemical matrix onto cryo-sectioned samples can be 
challenging due to the thaw rate of samples (Xu et al., 2016). Differing sample moisture 
content may also introduce inconsistencies by changing the solvent composition and 
conditions of matrix application. Previously, a two-step approach for matrix application 
has been reported in which the samples are dried by vacuum at room temperature or 
oven prior to matrix deposition (Li et al., 2016). Metabolite degradation is a concern 
when using dehydration procedures, particularly with prolonged heat treatments 
(Goodwin et al., 2010; Shariatgorji et al., 2014). As such, here we dried the sample 
section by lyophilisation prior to matrix application. This allowed preservation of native 
metabolite species and improved reproducibility in matrix application. Lyophilisation of 
the matrix-applied sample section was also employed as the final step in the freeze-spot 
approach, to maintain sample integrity. The removal of the solvent by lyophilisation 
also promotes the formation of a very fine crystal structure (Figure 4.2).  
 
The simplicity of the freeze-spot method compared to other commercial sprayers makes 
the technique easy to adapt. In our initial experiments, the freeze-spot method was 
investigated using 3 µL of DHB at 20 mg/mL in ACN:H2O (4:1, v/v) onto a cryo-
section of wheat seed. Although the volume of matrix was sufficient to cover the entire 
surface of the seed, the MSI image generated had reduced spatial information. A 
concern with spotting-based application is always the possibility of analyte 
delocalization. However, the time from application of the liquid matrix to freezing is on 
a sub-second time-frame and delocalisation needs to occur during this brief moment. To 
estimate the magnitude of delocalization, the increase in the spotting volume directly 
deposited onto the seed section was measured. Increasing the freeze-spot volume to 5 
µL not only ensures the complete coverage of the seed section to be acquired but also 
the increased diameter was measured from extracted ion images of DHB (m/z 585) as an 
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assessment of analyte spread from the origin. As shown in Figure 4.3, a slight 
broadening of the spot boundary was observed with both spot volumes. The measured 
delocalization is within the raster size for these images, suggesting that analyte 
redistribution should not affect image quality at the current image resolution. The 5 µL 
DHB solution at 20 mg/mL was ultimately selected in this application, as this 
composition provided the best spatial resolution for the assessment of surface 
metabolites on wheat seed sections. Typically, after matrix application, samples are 
dehydrated to prevent solvent/metabolite evaporation (Li et al., 2016). 
 
 
Figure 4.3 MALDI-MSI images comparing the signal intensity of m/z 585 ions found on 
seed sections when extracted using 3 µL (left) and 5 µL (right) of DHB solution at 20 
mg/mL. 
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The formation of salt adducts upon ionisation in MALDI-MSI can present a challenge 
to the analyst (Schaiberger and Moss, 2008; Keller et al., 2018); however, it can also 
provide benefit to efforts of metabolite identification (Petković et al., 2009; Lai and 
Wang, 2017). Some molecules undergoing ionization in the positive ion mode, will 
form adduct ions as [M+Na]+, [M+K]+ or [M+NH4]
+ (Mortier et al., 2004) rather than 
formation of a pseudomolecular ion [M+H]+. Sodium and potassium are abundant in 
biological systems, such that [M+Na]+ and [M+K]+ cations of metabolite species are 
commonly observed in MALDI-MSI analyses (Berry et al., 2011). Petkovic et al. 
(2009) have demonstrated adduct formation with sodiated DHB as well as adding 
complexity to spectral interpretation. Berry et al. (2011) also observed both [M+Na]+ 
and [M+K]+ ions of lipids in their analyses. In the described freeze-spot approach, 
sodiated and potassiated adduct formation was promoted by addition of sodium and 
potassium salts to the matrix solution.  The resultant effects on measured signal 
intensities were observed (Figure 4.4). Sucrose was applied to the centre of the sample 
followed by freeze-spot application of the DHB matrix (10 mM of NaOAc and/or 
KOAc). The overall signal intensity was at its highest when the DHB solution was 
potassiated, as demonstrated for the extracted ion image of sucrose (Figure 4.4). The 
sodiated adduct was also more pronounced than the protonated. The spatial resolving 
power also looked to improve with inclusion of KOAc; however, it is unclear if this is 
artefactual to the improved signal of the ion images. 
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Figure 4.4 MALDI-MSI images comparing the signal intensities of sucrose (m/z 343, 
m/z 365 and m/z 381) when extracted with the different variations of matrix: DHB only 
(A), DHB+NaOAc (B), and DHB+KOAc (C). The ion maps illustrated in the top row 
are from controls whilst images in the second row show a comparison with sections 
spotted with sucrose standard (1 mg/mL). 
 
The addition of potassium to the matrix prior to freeze-spot application proved 
particularly well suited to the spatial measurement of more complex sugars of 12 
carbons or greater, which readily form sodiated and potassiated adducts. Extracted ion 
images were generated for sugars up to and including the hexasaccharides (Figure 4.5). 
Whilst this demonstrated method was successful at providing comparable ion images 
for complex sugars including tetrasaccharide, pentasaccharide and the lesser complex 
disaccharides and trisaccharides, no signal was observed for the monosaccharides. Both 
sucrose (m/z 381) and 1-kestose (m/z 543) were also identified and well-resolved along 
with their region-specific spatial distributions, which is consistent with the fructan 
metabolism of barley (Peukert et al., 2014). These analyses demonstrated the freeze-
A  B  C  
[M+H]+ [M+Na]+ [M+K]+ 
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spot approach to be particularly well suited to small sample sections such as these, with 
all of the anticipated benefits already described.  
 
 
Figure 4.5 Wheat saccharide distribution across the surface of the cryo-sections using 
the developed MALDI-MSI method. The figure outlines the various sugars present with 
their associated adduct formation. 
 
The freeze-spot approach was initially conceived as a low-resource intensive approach 
to matrix-application for MALDI-MSI acquisitions. It was to be a matrix-application 
intermediate between precipitation of a dry matrix by sublimation and other common 
methods whereby the sample makes contact with the liquid matrix solution. The chilled 
stage permits higher freezing point solvents (or aqueous dilutions of), including 
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acetonitrile, to freeze rapidly, such that the sample is only exposed to the liquid solvent 
for a sub-second period of time. From a method development standpoint, the choice of 
and composition of chemical matrices for any given sample type can be easily 
determined and optimised using these described methods, whilst maintaining the spatial 
distribution that other pipette spotting approaches fail to accomplish. We also propose 
here that traditional MALDI may benefit substantially from use of the freeze-spot 
approach and/or the simple use of drying the applied matrix by lyophilisation, because it 
prevents hot-spot formation and therefore will likely improve the quantitation which can 
be achieved by MALDI. A more through assessment of the benefit of freeze-spot over 
application by sublimation in terms of the momentary contact of solvent with the 
sample surface will be determined in future studies. The resulting desorption of 
metabolites to the sample surface and the risk of metabolite losses will also warrant 
further investigation. 
 
4.5 Conclusion 
 
The described simple and robust freeze-spot method for MALDI-MSI is cost effective, 
requiring substantially less chemical matrix, eliminating the requirement for large 
volumes of matrix solution or the need for sophisticated automated sprayers for matrix 
application to small sample sections. The delocalization of analytes was successfully 
minimised by the rapid freezing of the matrix, and lyophilisation to maintain the native 
spatial dimensionality of metabolites in the sample, whilst also forming a fine crystal 
structure for efficient ionisation without the formation of hotspots. The affordability and 
simplicity of this method makes the approach practical and readily adaptable by other 
users for various matrices. 
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Optimisation of MALDI-MSI matrix improves spatial resolution of lipid species in 
fibrotic lung tissue 
 
Adapted from Nambiar, S.; Trengove, R. D.; Gummer, J. P. A.; Moodley, Y.; and 
Bong, S. H. (2018) “Optimisation of MALDI-MSI matrix improves spatial resolution of 
lipid species in fibrotic lung tissue” Ready for submission to Progress in Lipid Research 
 
5.1 Abstract 
 
Idiopathic pulmonary fibrosis (IPF) is an irreversible, chronic and progressive lung 
disease with unresolved aetiology. Lipids present promising targets for diagnostic and 
therapeutic intervention due to their role in signalling and as critical determinants in 
cellular energetics. A number of studies have recently highlighted the pathophysiology 
of lipid dysregulation in chronic lung diseases, such as chronic obstructive pulmonary 
disease (COPD; Telenga et al., 2014; t’Kindt et al., 2015) and asthma (Berry et al., 
2017; Hough et al., 2018). Mass spectrometry imaging (MSI) provides the means to 
spatially resolve the distribution of biomolecules, pharmaceuticals and xenobiotics in 
tissue sections without the use of labels, tags or reporters (Schultz et al., 2019). This 
approach promises to offer fresh insights into the biochemistry of complex interstitial 
lung diseases like IPF. Specifically, we employed MSI to characterize changes in lipid 
signatures between IPF and healthy control tissues and identify putative biomarkers 
associated with IPF. It is well-know that the addition of ammonium salts can lead to 
suppression of matrix-assisted laser desorption ionisation (MALDI) matrix clusters; the 
salt dissociates potential matrix adducts and decreases matrix cluster formation (Ucal 
and Ozpinar, 2018). We further refined the MSI technique by optimising the amount of 
inorganic salts in MALDI matrix to improve the intensity and spatial resolution of lipid 
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species such as ceramides, lysophosphatidylcholines, phosphatidylcholines, 
phosphatidylethanolamines, sphingomyelins and triglycerides. The lipids in healthy and 
IPF tissue sections (20µm) were then resolved using MALDI-quadrupole time-of-flight 
(Q-TOF) MSI and data were interrogated by High Definition Imaging (HDI) software 
by Waters to generate ion intensity maps. Putative identification of lipids was achieved 
by accurate mass measurement and matched against lipid databases including LIPID 
MAPS and LipidBlast. This optimised method provides a new approach to enhance the 
visualisation of lipid distribution in IPF and may provide users with additional 
metabolite information that can complement existing histopathological assessments, as 
well as aid in the diagnosis of disease. 
 
Keywords: MALDI, imaging, lung, lipids, IPF 
 
5.2 Introduction 
 
Idiopathic pulmonary fibrosis is a chronic, progressive and fibrosing interstitial 
pneumonia with unresolved aetiology (Diamantopoulos et al., 2018). The underlying 
histopathological pattern is one of interstitial pneumonia in the absence of secondary 
causes or associations (Raghu et al., 2011). Idiopathic pulmonary fibrosis has a poor 
prognosis with a median survival of three to five years from diagnosis (Raghu et al., 
2011; Fabrellas et al., 2018); however, there is considerable heterogeneity among 
patients in disease course (Poletti et al., 2013). At present, there are limited therapeutic 
interventions available to patients. 
 
Clinicians and researchers currently rely on clinical data such as patient history, 
physical examinations including radiology, pulmonary function tests and 
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histopathological identifications to diagnose patients with IPF (Nakamura and Suda, 
2015; Fabrellas et al., 2018). These tests, however, do not reflect the underlying 
pathophysiological mechanisms of disease and does not adequately allow for the sub-
phenotyping of patients with IPF. This presents a major limitation for both clinical care 
and research. 
 
Lipidomics is a promising strategy for disease-specific biomarker discovery as there is 
growing evidence to suggest a role of cellular energy metabolism in lung fibrogenesis 
(Dautel et al., 2017). Lipids are key cell membrane constituents (Pöyry and Vattulainen, 
2016) and serve critical physiological roles including regulation of energy metabolism 
(Dautel et al., 2017), cellular signalling (Kyle et al., 2018) and trafficking of immune 
cells (Hubler and Kennedy, 2016). Dysregulated lipid (Carter et al., 2017) and energy 
(Kang et al., 2016) metabolism have been shown to influence fibrosis. Current methods 
for chemical localisation of metabolites such as staining with Ehrlich’s reagent (Jarman 
et al., 2014) and Nile Red (Sunaga et al., 2013) can be applied to frozen diseased lung 
sections. However, these can only reveal the distribution of a defined number of 
biomolecules. Mass spectrometry imaging (MSI) techniques, on the other hand, offer a 
means of mapping thousands of ionised lipid signatures within different tissue subtypes, 
and can potentially generate a global profile of disease based on metabolite distribution 
and abundance. 
 
A number of studies have applied MSI to spatially resolve small molecules in lung 
diseases. Römpp and Spengler (2013) identified region-specific phospholipids and 
peptides in lung carcinoma samples showing high correlation with histological 
assessment, while Baijnath et al. (2016) used MSI to explore the distribution of small 
molecules and drug metabolites in inflated lungs of a rat model. More recent advances 
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in global lipidomic approaches have shown lipid compositional changes in post-natal 
lung development (Dautel et al., 2017) and in radiation-injured lung (Carter et al., 2017).  
MALDI-MSI is the most widely used method applied to lipids (Bowman et al., 2018). 
Sectioned tissues coated with MALDI matrix are rastered by a laser beam across the 
tissue surface while the MS measures the ionised lipids at each coordinate (Walch et al., 
2008; Carter et al., 2016). This technique is appealing because the distribution and 
composition of many analytes can be assessed in a single experiment. Image generation 
is achieved by plotting the intensities of analyte ions as a function of the x-y coordinates 
of the sample section (Prentice et al., 2015). MALDI-MSI has been commonly used to 
investigate spatial distribution of intact proteins and peptides on various mammalian 
tissues (Berry et al., 2011; Prentice et al., 2015). The high mass resolution of the 
technique has also been found to resolve isobaric lipid distribution in tissue (Carter et 
al., 2017). Studies by Desbenoit et al. (2014) and Carter et al. (2017) further 
demonstrated that the abundance of lipid signatures in MALDI images strongly 
correlates with lipid accumulation within specific regions of the tissue.  
 
Here, we utilized a recently optimised matrix application technique termed “freeze-
spot” to address the optimisation requirements associated with MSI-based sample 
preparation including the amount of matrix required and, matrix uniformity (Nambiar et 
al., unpublished). To improve the sensitivity of the method, we optimised the formation 
of adducts using various salts such as sodium, potassium and ammonium acetate. In 
particular, the addition of potassium acetate resulted in improved mass spectra quality 
as well as feature intensities of MALDI images. We then applied this technique to 
spatially-resolve the changes in lipid composition and distribution in IPF as well as 
healthy control tissue samples. 
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5.3 Materials and Methods 
 
5.3.1 Chemicals  
 
Ultra-pure LC-MS grade solvents including acetonitrile (ACN), isopropanol (IPA), 
water (H2O) and trifluoroacetic acid (TFA) were purchased from Thermo Fisher 
Scientific (Massachusetts, USA). Sodium acetate (NaOAc), potassium acetate (KOAc), 
ammonium acetate (NH4OAc) and MALDI matrix 2,5-dihydroxybenzoic acid (DHB) 
were obtained from Sigma-Aldrich (Castle Hill, Australia). Lipid standards including 
ceramide (Cer d18:1/17:0), phosphatidylethanolamine (PE 15:0), phosphatidylcholine 
(PC 15:0) and sphingomyelin (SM d18:1/17:0) were purchased from Avanti Polar 
Lipids (Alabaster, USA) while lysophosphatidylchole (LysoPC 15:0) and triglyceride 
(TG 15:0) standards were sourced from Sigma-Aldrich. Stock lipid standards were 
prepared in methanol (MeOH) and the working concentrations of all lipids at 1 µg/mL 
were prepared by dilution in IPA. 
 
5.3.2 Biological samples 
 
A total of 20 frozen lung biopsied samples (10 from IPF patients and 10 healthy 
controls) were obtained from the Alfred Lung Fibrosis Biobank (Alfred Health, Victoria, 
Australia) and stored at -80 °C until further analysis. Sample handling and material 
transfer was approved by The Alfred Ethics Committee (Approval number: 336/13) and 
the experimental protocol used for this work was approved by the Murdoch University 
Human Research Ethics Committee (Approval number: 2017/253). 
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5.3.3 Sample preparation 
 
All microscopy glass slides were thoroughly rinsed with IPA and placed in the 
cryotome at -17 °C prior to being used. Frozen biopsied lung sample were mounted to a 
chuck by placing the tissue immediately on a drop of water (on the chuck) upon transfer 
into the cryotome.  Each tissue sample was then cryo-sectioned to 20 µm thickness and 
subsequently transferred onto a clean, pre-chilled glass slides. This was achieved by 
gently warming the rear of the slide with a finger to allow the section to thaw and attach 
to the slide. All prepared sections were stored at -80 °C until matrix application. 
 
5.3.4 Freeze-spot matrix application 
 
An acidified hydroxyl matrix DHB was chosen as the matrix of choice as it has been 
shown to be suitable for the detection of lipids (Stoyanovsky et al., 2014; Dowlatshahi 
et al., 2016). The DHB matrix was prepared at a concentration of 20 mg/mL in 80 % 
ACN (0.1 % TFA). To promote sodium ([M+Na]+), potassium ([M+K]+) or ammonium 
([M+NH4]
+) adduct formation, the DHB matrix solution was prepared with 10 mM of 
either NaOAc, KOAc or NH4OAc,  respectively. 
 
Application of the DHB matrix solution was performed using the freeze-spot approach 
(Nambiar et al., manuscript in preparation). Briefly, the mounted sample sections were 
placed onto a stainless-steel stage, pre-chilled on dry ice and 5 µL DHB (20 mg/ml) 
matrix was transferred onto the sample section by pipette. The solvent immediately 
froze upon contact with the sample. The glass slides were transferred to a polypropylene 
50-mL centrifuge tube, which was sealed, submerged in liquid nitrogen and the solvent 
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removed by lyophilisation with a Labconco Freezone 2.5 Plus freeze-dryer that is 
depressurized with a JLT-10 JAVAC high vacuum pump. 
 
5.3.5 MALDI-MSI acquisition 
 
All MALDI-MSI analyses were performed using the Water Synapt G2S mass 
spectrometer equipped with an orthogonal MALDI ion source and an Nd:YAG laser 
(Waters Corporation, Manchester, U.K.). Prior to analytical acquisition, digital scans of 
the tissue sections were obtained using an Epson WorkForce Pro WP-4540 scanner 
(Epson America, Inc.) and then imported into MALDI Imaging Pattern Creator software. 
All data were acquired in positive mode operating with a 1,000 Hz firing rate and 350 J 
laser energy over a mass range of m/z 50 to 1200. From each irradiated spot, a full mass 
spectrum consisting of signals from protonated molecular species from the desorbed 
tissue region was noted. The spectra generated were then processed in MassLynx 
(Waters Corporation, Manchester, UK) to allow for signal intensities of the 
corresponding ions to be determined. The MSI images were acquired at a spatial 
resolution at 600 laser shots per position and ion images were generated with High 
Definition Imaging (HDI) software (Waters Corporation, Manchester, U.K.). The heat 
maps of specific ions generated corresponded to the relative abundance of ions present 
over the entire imaged surface. 
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5.4 Results and Discussion 
 
5.4.1 Potassium adducts enhanced MALDI-MSI intensities of lipids 
 
The formation of adducts during ionisation can potentially compromise the quality of 
the mass spectra generated (Leite et al., 2004; Bauer et al., 2018). The unintended 
formation of salt adducts due to exposure from the storage vials, pipette tips or even the 
glass slides used can present difficulties for the detection and identification of molecules 
at low abundances. The resulting adducts reduce signal intensities by splitting the ions 
into multiple mass peaks and supress the ionisation of low abundance peaks (Leite et al., 
2004). The presence of these inorganic lipid adducts are inevitable in MALDI-based 
techniques and its formation upon ionisation have been reported by Angel et al. (2012), 
and Wang et al. (2017). Studies by Zhu and Papayannopoulos (2003) and Leite et al. 
(2004) showed that the reduction or removal of these adduct ions can improve the 
detection of peptides at low concentration. However, mobile-phase additives such as 
ammonium acetate is commonly used to improve both LC separation and detection of 
lipids (Cajka and Fiehn, 2014). Due to their strong affinity for alkali metals, various 
adducts of alkali metals and ammonium cations have been used to improve the intensity 
of lipids such as triacylglycerols (Hsu and Turk, 1999; Lin and Arcinas, 2008) and 
phospholipids (Knittelfelder et al., 2014) using electrospray ionisation (ESI) techniques. 
 
Angel et al. (2012), Wang et al. (2017) and Rush and Breemen (2018) used DHB as the 
matrix of choice for lipid extraction and promotion of ionisation. In this study we 
encouraged the formation of lipid [M+Na]+, [M+K]+ and [M+NH4]
+ adducts using DHB 
prepared with inorganic salts that consists of a metal cation to investigate their effects 
on lipid resolution and intensity. Figure 5.1 shows the total ion chromatogram (TIC) of 
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lipid standard mixture extracted with DHB and DHB spiked with NaOAc, KOAc and 
NH4OAc. The TIC from DHB spiked with KOAc showed the highest intensity at 
approximately 2 x 106 counts. This was consistent with the observations of Birdsall et al. 
(2016) where the intensities of the [M+K]+ ions were two-fold the intensity of [M+Na]+ 
ions generated by ESI. Wang et al. (2017) also reported increase in [M+K]+ ions of 
phospholipid species from MALDI imaging using DHB. These studies utilised matrices 
prepared in solvents without salt additives. Rush and Breemen (2018) were also unable 
to selectively reduce the formation of both [M+K]+ and [M+Na]+ adducts using 
ammonium salts; however, they were successful at suppressing the ionisation of PCs.  
 
Figure 5.1 The total ion chromatograms (TIC) of the lipid standards mixture spotted on 
a glass slide at 1 µg/mL and extracted with (A) DHB with NH4OAc ([M+NH4]), (B) 
DHB with KOAc ([M+K]), (C) DHB with NaOAc ([M+Na]) and (D) DHB only 
([M+H]). 
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To further demonstrate the effects of adduct formation, six lipid classes including 
LysoPC, Cer, PE, PC, SM and TG were examined. The ions corresponding to each of 
the four adducts were extracted from the TIC. The proton adduct [M+H]+ has previously 
been found to be the dominant ion formed during ESI (Dudkowska et al., 2018) while 
[M+Na]+ and [M+K]+ are the most common when using MALDI (Jovanovic et al., 
2018). While [M+NH4]
+ ions are routinely generated due to the addition of solvent 
buffers and during metabolite extraction, these results showed poor formation of 
[M+NH4]
+ lipid adducts during ionisation by DHB containing NH4OAc. This further 
confirmed the observations of Rush and Breemen (2018) who showed the suppression 
of PC ionisation when ammonium additives were applied. 
 
Interestingly, the addition of NaOAc resulted in the formation of the [M+H]+, [M+Na]+ 
and [M+NH4]
+  adducts, with the [M+NH4]
+ adduct showing the highest intensities for 
all six lipids tested. This finding is potentially indicative of impurities in the salt 
additive but this observation is still relevant since the NH4 was in excess relative to the 
other species been demonstrated. Figure 5.2 shows the extracted ion chromatograms 
(XICs) of each of the four adducts for each lipid when ionised using DHB containing 
NaOAc. The peak quality of all adducts were comparable to each other except for the 
potassium adduct where the associated [M+K]+ ions for CE and PE were not evident. In 
addition, the [M+K]+ spectra for PC, SM and TG showed increased background. This is 
consistent with the observations of Rush and Breemen (2018) who also demonstrated 
that the use of ammonium buffers affected the relative abundance of [M+H]+, [M+Na]+ 
and [M+K]+. We therefore hypothesise that the ion signal of [M+NH4]
+ species were 
improved when ammonium buffers were used in combination with the DHB matrix. To 
the authors’ knowledge the exact mechanism by which sodium promoted the formation 
of ammonium adducts is yet to be reported. However, we speculate that by increasing 
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competition for ionisation sites on the lipid molecule in favour of the ammonium cation, 
the lesser-abundant cations are less likely to adduct unless they were usually the most 
preferentially formed. For lipids, the [M+H]+ was less readily formed during ionisation, 
and as such the ammonium addition decreases the adduction. However [M+Na]+ and 
[M+K]+ which were more readily formed were still observed as they were conceived to 
be more favourable than [M+NH4]
+ formation. 
 
Of note, the use of KOAc to encourage adduct formation of these lipids was shown to 
have improved the relative abundance of [M+K]+ compared to [M+H]+, [M+Na]+ and 
[M+NH4]
+ ions by at least two orders of magnitude. All four adduct species were 
identified for LysoPC. For PC, SM and TG, [M+K]+ showed improved abundance while 
[M+H]+ and [M+NH4]
+ showed poor ion spectra (Figure 5.3). For Cer and PE, only the 
[M+K]+ ions were detected. In summary, [M+K]+ ions were the only adduct type that 
were well-resolved in all six lipids whilst supressing the signal of [M+H]+, [M+K]+ and 
[M+NH4]
+ ions. Figure 5.3 illustrates the MALDI-MSI ion intensity maps which 
showed the abundance of these adduct species within the extracted lipids. 
 
The addition of cations was clearly important in MALDI-MSI experiments for the 
detection of lipid species. Sugiura and Setau (2009) and Griffiths and Bunch (2012) 
have reported that the addition of either NaOAc or KOAc to the matrix led to reduced 
signal intensities of the protonated adducts of lipids by MALDI. However, Griffiths and 
Bunch (2012) showed increased [M+K]+ formation of PCs in rat brain homogenate by 
the addition of KOAc but with a suppression of the ion counts, in agreement with 
Sugiura and Setau (2009). Other additives such as caesium chloride and lithium nitrate 
have also been applied to MALDI matrices. These appeared to reduce the spectral 
complexity and improved identification of unidentified metabolites by allowing 
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unambiguous assignment of caesium-lipid and lithium-lipid adducts (Griffiths and 
Bunch, 2012; Griffiths et al., 2013). 
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Figure 5.2 Extracted ion chromatograms of the lipid adducts [M+NH4]
+, [M+K]+, [M+Na]+ and  [M+H]+ denoted by A, B, C and D, respectively. All 
six lipid standards were extracted with DHB containing NaOAc. 
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Figure 5.3 Extracted ion chromatograms and ion intensity maps of the lipid adducts generated by MassLynx and HD Imaging software, respectively. 
All six lipid standards were extracted with DHB containing KOAc and their associated adducts [M+NH4]
+, [M+K]+, [M+Na]+ and  [M+H]+ are 
denoted by A, B, C and D, respectively.  
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5.4.2 MALDI images of biopsied lung sections 
 
This study builds on the published research of Carter et al. (2015 and 2017) which 
focused on the characterisation of lipids in lung parenchyma using MALDI-MSI. Here, 
we optimised the addition of KOAc in DHB matrix to promote [M+K]+ adduct 
formation to investigate the spatial distribution of various lipid species including 
sphingolipids, phospholipids and triglycerides in IPF and healthy tissue biopsies. 
 
Figure 5.4 shows the spatial resolution of two ions m/z 494.24 and m/z 897.75 compared 
to optimal light microscopy images obtained at 40x objective magnification. The 
extracted ion m/z 494.24 was shown to be well-distributed within the rastered tissue 
region, whereas ions of m/z 897.75 were distributed along the tissue periphery. A closer 
inspection of both the optical image and ion intensity map revealed that m/z 897.75 was 
likely to be a matrix-related ion and not a lipid-specific ion. The m/z value did not 
match any of the calculated theoretical masses of the lipid adducts of interest and the 
ion was peripherally distributed around the rastered tissue. This was important as it 
demonstrated the ability of the method to discriminate between lipid-specific ion and 
matrix ions in cryo-sectioned lung tissues. 
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One of the challenges of MALDI ionisation is the high matrix background resulting 
from the use of organic matrices like DHB (Fujimura and Miura, 2014). Studies by Le 
et al. (2013), Fujimura and Miura (2014) and Lee et al. (2016) recognised that some 
background matrix ions can have similar intensities to analyte ions and can interfere 
with detection and identification of the target analytes. In this study, the enhanced signal 
intensities resulting from the addition of KOAc was advantageous as it allowed for the 
improved discrimination of lipid analytes from the background ions. Of note, features 
with m/z 520.29, m/z 744.38 and m/z 702.33 were identified as LysoPC, PC and PE 
based on their [M+K]+ adduct accurate mass. Figure 5.5 illustrates a loss of signal 
intensities for LysoPC, PC and PE ions in IPF tissue sections compared to healthy 
control tissues.  
Figure 5.4 The optical 
images (A and C) of 
sectioned lung tissue 
obtained by light 
microscopy at 40x 
magnification with an 
auto exposure mode and 
the corresponding 
MALDI-MSI images (B 
and D) generated at 20 
µm resolution. 
A B 
C D 
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Figure 5.5 MALDI-MSI images showing decreased signal intensities of LysoPC, PC 
and PE ions in IPF tissues compared to healthy control samples. Representative 
hemotoxylin and eosin (H&E) stained IPF and healthy tissues were also shown for 
comparison. 
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The changes in lipid profiles of diseased lung tissues are well-studied. Naz et al. (2017) 
used LC-Orbitrap MS to elucidate the role of lysophosphatidic acid (LysoPA) in lung 
function, specifically forced expiratory volume in 1s (FEV1), from COPD patients, 
smokers with normal lung functions and healthy (never-smoked) individuals. In this 
study, we showed that LysoPC, which is a precursor of LysoPA, was down-regulated in 
IPF compared to health control tissues. This suggested that the LysoPA signalling 
pathway may be involved in disease mechanism or symptoms. LysoPA, a bioactive 
glycerophospholipid, has been shown to be associated with asthma (Ackerman et al., 
2016), atherosclerosis (Gu et al., 2017), cancer (Ha et al., 2018) and fibrosis (Rancoule 
et al., 2017). LysoPA is produced through the hydrolysis of phosphatidic acids by 
phospholipase which are located in cell membranes. The majority of LysoPA is 
produced by the enzymatic cleavage of LysoPC and lysophosphatidylserine by 
lysophospholipase D activity. In IPF, type 2 alveolar epithelial cell injury is believed to 
initiate the fibrotic process. Following an injury, dipalmitoylphosphatidylcholine 
(DPPC), a major surfactant lipid component, is degraded to LysoPC by phospholipase 
A2 activity in the type 2 alveolar epithelial cells. However, our study appeared to 
contradict this as the IPF tissue sections showed reduced intensities of LysoPC 
compared to healthy samples. The precise reduction in LysoPC levels in IPF tissue has 
not been determined as the current method was unable to quantitate lipid abundance. 
Further quantitative work has been envisioned where known concentrations of lipid 
standards will be spiked to generate calibration curves based on MSI spectral intensities. 
 
Lung surfactant consists of type 2 alveolar cells and is a complex mixture of 
phospholipids, with PCs accounting for approximately 90% of surfactant composition. 
The PCs play an important role in reducing surface tension at the air-water interface of 
the alveolus. Compared to healthy tissues, IPF tissues have a lower composition of PCs 
 Chapter 5 
 
161 
 
and this appeared to be consistent with our observations of PC intensities in Figure 5.5. 
A loss or reduction of PCs has adverse effects on the surface tension of the lungs and 
can lead to alveolar collapse. In lung diseases such as acute respiratory distress 
syndrome (ARDS; Fessler and Summer, 2016), pneumonia (Facco et al., 2014), 
sarcoidosis (Devendra and Spragg, 2002) and IPF (Schmidt et al., 2002; Tan et al., 
2016), a decrease in PCs and large surface aggregates have been associated with 
impairment of the surface tension-lowering properties of surfactant. Pulmonary 
surfactant also plays a key role in protecting the underlying epithelium from toxins and 
microbes that are inhaled into the lungs. Fessler and Summer (2016) noted that 
pathogens may drive some of these changes in lipids since Pseudomonas aeruginosa 
(Agassandian et al., 2007) and human adenovirus type 5 (Miakotina et al., 2007) were 
both reported to reduce PC secretion from the type 2 alveolar cells.  
 
We observed a reduction in PC intensities in IPF tissue sections and this agreed with the 
published research of Schmidt et al. (2002) and Sunaga et al. (2013) on altered fatty 
acid (FA) composition of surfactant lipids. Pathway analysis conducted by Yin et al. 
(2017) and Menon et al. (2017) revealed that PCs and FAs such as palmitoleic acid and 
oleic acid are involved in mTOR signalling pathway. Tan et al. (2016) showed that the 
mTOR complex was a highly conserved intracellular serine/threonine kinase and mTOR 
expression in pulmonary fibrosis patients were significantly correlated with fibrosis and 
decreased lung function. This suggested that PC may be conceived as a prognostic 
marker of pulmonary fibrosis as hypothesised by Park et al. (2014). Phosphatidic acid 
interacts directly with the binding domain in mTOR, and this interaction affects the 
mTOR’s ability to activate downstream effectors such as PCs (Menon et al., 2017).  
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PE is the second most abundant phospholipid found in biological membranes. The 
reduction in intensities of PE in the IPF tissue compared to healthy control supported 
the observations of Hu et al. (2015) where the hepatic PE levels were significantly 
reduced in a bleomycin-induced mice model. Hu et al. (2015) suggested that the 
reduction of PE species was due to the compartmental effects of phosphatidylserine 
(PS) biosynthesis which occurs in the mitochondria. Farine et al. (2015) and Leithner et 
al. (2018) further reported significant reductions in both PC and PE levels in cancer 
cells as a consequences of increased PS biosynthesis. A recent study by Vazquez-de-
Lara et al. (2018) demonstrated that PE induced an anti-fibrotic phenotype in an 
experimental model of lung fibrosis. The study showed that PE contributes to the 
inhibition of collagen expression and that early administration of PE diminishes lung 
fibrosis in vivo.  
 
MSI is a rapidly emerging application of mass spectrometry that allows for the analysis 
and spatial visualisation of thousands of analytes without the need for tissue labelling. It 
is clear that more research is required to develop methods that can provide absolute 
quantitation as a function of ionisation intensity. While recent work by Hansen and 
Janfelt (2016), Nishimura et al. (2017) and Nazari et al. (2018) has introduced internal 
standards for quantitative MSI, such efforts needs further refinement due to matrix 
inhomogeneity, ion suppression or analyte extraction efficiencies that can result in 
suppressed signal (Gemperline et al., 2014). Bergman et al. (2016) and Duncan et al. 
(2018) further demonstrated that the addition of deuterated standards to a nano-
desorption electrospray ionisation (DESI) solvent beam enabled compensation of 
sample-matrix effects, which enhanced visualisation and interpretation of the ion 
images. Bergman et al. (2016) and Duncan et al. (2018) also performed tandem mass 
spectrometry (MS/MS) on both deuterated standards and endogenous compounds such 
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as neurotransmitters and eicosanoids to determine the ratio of analyte intensity to 
standard intensity as the basis of quantitation. These present promising avenues for 
future work.  
 
5.5 Conclusion 
 
Here, we demonstrated the utilization of a new matrix application technique, termed the 
“freeze-spot” method, and successfully promoted potassium adduct formation for MSI 
of lung tissues. The improvement in mass spectral quality and enhanced signal 
intensities resulted in the generation of high-quality images with the resolution of six 
lipid species of interest. The MALDI-MSI method allowed for the visualisation of the 
lipids and demonstrated the differences in relative intensities and abundances of PC, PE 
and LysoPC between diseases and healthy control tissue biopsies. Significant 
differences were observed in lipid species involved in LysoPA and mTOR signalling 
pathways, as well as surfactant PCs. Further studies are envisioned using quantitative 
MSI approaches and potential further co-registration of ion maps to conventional 
hematoxylin and eosin stained sections to allow for a deeper investigation of lung 
pathology. 
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6.1 General Discussion 
 
This PhD project has demonstrated the effectiveness of using UPLC-QTOF-MS and 
MALDI-MSI to deliver improved resolution, specificity and dimensionality for the lipid 
profiling of plasma and tissue samples of chronic lung diseases. Chapter 1, entitled 
“Metabolomics in chronic lung diseases: a practical review for clinicians”, presented a 
comprehensive examination of experimental strategies and its utility in improving the 
understanding of biochemical changes associated with diseases such as COPD, asthma 
and IPF. This chapter provided a critical review of recent published outcomes, 
highlighting the major metabolic pathways associated with pathogenesis as well as 
identifying potential biomarkers of interest that can aid in the diagnosis, prognosis and, 
ultimately, treatment of disease.  
 
Chapter 2 is focused on the application of untargeted metabolomics to provide global, 
unbiased profiling of COPD and IPF. A total of 65 clinical plasma samples were 
assessed using UPLC-QTOF-MS, of which 21 were obtained from COPD patients, 24 
from IPF diagnosed patients and 20 from healthy control subjects. The aim of this study 
was to use metabolomics to further the understanding of changes that underpinned both 
chronic lung conditions. The use of multivariate statistics including PCA and OPLS-DA 
showed distinct differences in the metabolomic profiles of plasma from COPD and IPF 
patients compared to healthy individuals. This study identified unique lipid mediators 
such as linoleic, palmitoleic and oleic acids which suggested a dysregulated lipid 
metabolism indicative of severe lung inflammation and progression of fibrosis (Sunaga 
et al., 2013; Daabis et al., 2016). This study also revealed significant down-regulation 
of arachidonoyl tyrosine, bilirubin, dihydrotestosterone and lysoPC in both COPD and 
 Chapter 6 
 
176 
 
IPF samples that implied increased oxidative stress within the lung (Brown et al., 2017; 
Zhao et al., 2017).  
 
Chapter 3 involved the application of a data independent acquisition method, termed 
SONAR, to complement the UPLC-QTOF-MS resolution of lipid species between 
“stable versus progressor” IPF patient groups. The availability of two diseased groups 
of IPF were important as it allowed for the characterisation of global lipid changes 
associated with disease progression. SONAR DIA technique facilitated improved lipid 
identification of a number of spiked deuterium-labelled lipid standards that were 
representative of lipids found in human plasma. The isolation of the molecular ions 
prior to fragmentation allowed fragment ions to be readily assigned to its relevant 
precursors for specific lipid identification using LIPID MAPS for structural elucidation 
and confirmation. In addition, the lipid profiles from 30 patients diagnosed with 
progressive IPF showed changes in lipid plasma composition when compared to the 30 
stable subjects. A number of triglycerides and glycerolipids that were unique lipid 
markers of IPF progression were identified. These lipids were found to be intermediates 
of key signalling pathways associated with lung inflammation and fibrosis (Yui et al., 
2015; Yan et al., 2017; Kulkarni et al., 2018) and hold considerable promise as 
biomarkers for IPF. While the current sensitivity of SONAR was lower than 
conventional TOF-MS acquisition, the generation of quantitative MS/MS data with 
reduced background interferences were highly advantageous. In addition, SONAR-
acquired data were significantly smaller in size compared to the DIA methods such as 
MSE and were comparable in performance in terms of identification precision and 
quantitation accuracy (Meyer and Schilling, 2017).  
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In Chapter 4, a novel and cost-effective preparative method for MALDI referred to as 
“freeze-spot” was demonstrated. The deposition of matrix in MALDI-MSI was 
important to enable simultaneous extraction of metabolites from tissue sections as well 
as maintain the spatial dimensionality of endogenous metabolites (Fujimura and Miura, 
2014; Gemperline and Li, 2014). The study used wheat seed sections to demonstrate 
extraction efficiency and reliability, whilst maintaining the spatial resolution of the 
acquired MALDI-MSI images. This freeze-spot approach utilized a chilled stage which 
permitted rapid freezing of matrix followed by a lyophilisation step to prevent hot-spot 
formation and further improve image quality. The addition of sodium and potassium 
acetate to the matrix prior to freeze-spot application resulted in improved spatial 
measurement of complex sugars of 12 carbons or greater, which readily form sodium 
and potassium adducts. Both sucrose (m/z 381) and 1-kestose (m/z 543) were identified 
and well-resolved along with their region-specific spatial distributions, which was 
consistent with the fructan metabolism of barley (Peukert et al., 2014). These analyses 
demonstrated that the freeze-spot approach using DHB matrix prepared with inorganic 
salts resulted in increased spatial resolving power of small molecules such as 
oligosaccharides in seed sections.    
 
In the final study, 10 healthy and 10 fibrotic tissues were profiled using MALDI-MSI 
previously optimised with the freeze-spot methodology. The MSI technique developed 
was further enriched by promoting potassium adduct formation to improve spatial 
resolution of lipid species such as triglycerides, sphingolipids and glycerophospholipids. 
The results of this study showed a number of interesting changes in lipid composition of 
IPF tissues compared to healthy controls. MALDI-MSI of tissues were achieved using 
DHB matrix spiked with sodium and potassium acetate salts for the visualisation of a 
number of lipids of interest. The method showed differences in relative intensities and 
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abundances of PC, PE and LysoPC between diseases and healthy control tissue biopsies. 
Significant differences were also observed in lipid species involved in LysoPA and 
mTOR signalling pathways, as well as surfactant PCs. Of note, both SONAR DIA 
acquisition (Chapter 3) and MSI analysis (Chapter 5) identified similar classes of lipids 
(TG, PE, LysoPC and PC) that were potential determinants in the pathophysiology of 
the IPF lipidome. 
 
6.2 Current challenges  
 
As an emergent sub-discipline of metabolomics, lipidomic profiling is generating 
considerable interest due to the ubiquity of lipids as functional building blocks and its 
roles in health and disease. Nonetheless, a number of technical challenges remain. 
 
In particular, current lipidomic pipelines are unable to resolve more than fifty percent of 
lipid species that constitute the lipidome (Lydic and Goo, 2018). The existing analytical 
limits of detection mean that the analysis of some classes of lipids such as eicosanoids 
require specialised analysis using targeted methodologies (Sorgi et al., 2018). 
Additional derivatisation or hydrolysis may also be required for total lipids in some 
cases (De Paola et al., 2017; McDonald et al., 2012). Moreover, the large number of 
isobaric species may require bespoke chromatographic separation unique to the lipids of 
interest. Some of these limitations can be overcome by the improvements in MS 
platforms and modalities which continue to improve in sensitivity, specificity and 
resolving power. Next-generation MS instrumentation with more effective 
chromatography and sample ionisation, such as nano-ESI or gas-phase separation 
techniques such as ion-mobility, show promise (Keating and Glish, 2018). Indeed, the 
application of ion-mobility MS has the potential to enhance the separation of lipids and 
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improve isomer resolution due to its ability to exact cross-collisional information (Hinz 
et al., 2017). 
 
6.3 Future Work 
 
The work presented herein highlighted the importance of lipids as potential indicators of 
disease and presents a pipeline to assess compositional changes of lipids in a number of 
disease states. Future work will immediately focus on larger sample cohorts to increase 
statistical significance and validation of lipids identified in this study, as well as 
evaluate their utility as clinical diagnostics using targeted methodologies such as 
tandem LC-MS or enzyme-linked immunosorbent assay (ELISA).  
 
An important aspect of future work will be the correlation of clinical metadata (such as 
age, sex, disease state, smoking history and lung function tests) against the lipidomic 
profile of the sampled individual or groups.  Observational data, when used to 
complement the findings of metabolomics analyses, can offer additional means to 
phenotype disease (Trivedi et al., 2017). This is especially evident where 
complementary metabolite and clinical metadata can contribute to the effectiveness of 
subsequent lines of inquiries such as chemometrics (Trivedi et al., 2017). 
 
Additional lipidomic profiling of other chronic lung diseases such as asthma and 
sarcoidosis will also be interesting to determine if the biochemical changes encountered 
in this work prevails across a larger spectrum of chronic lung conditions. Future work 
can also be performed to measure lipid kinetic and flux using stable isotope-labelled 
standards in diseased versus healthy samples. In-depth fluxomics analyses is expected to 
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provide additional insights into the rate of lipid metabolism at the molecular level and 
can facilitate a deeper understanding of their roles in IPF. 
 
Future work will also be focused on the development of new quantitative approaches to 
MSI. This will involve the generation of calibration curves by spiking of isotopically-
labelled internal standards directly onto the tissue section followed by MALDI-MSI 
acquisition. Gentler, ambient ionisation techniques including desorption electrospray 
ionisation (DESI) and atmospheric pressure (AP)-MALDI can also be evaluated directly 
on untreated histological samples and has the potential to provide in situ analysis in 
clinical settings. 
 
6.4 Conclusion 
 
The application of untargeted metabolomics and imaging mass spectrometry in 
combination with multivariate statistical approaches were successful at revealing unique 
markers which can be used to correlate metabolic mechanisms and pathways 
fundamental to disease development. The application of a unique DIA mode such as 
SONAR can potentially enhance the specificity of data acquired using UPLC-QTOF-
MS. Finally, the use of the freeze-spot approach optimised with potassium adduct 
formation for MSI acquisition provides a new avenue to improve the visualisation of 
lipid distribution in IPF tissues and may provide users with additional metabolite 
information that can complement existing histopathological assessments, and aid in the 
diagnostic of the disease. 
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... and looks like I’ve hit my lipid. 
 
 
